<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">88573</article-id><article-id pub-id-type="doi">10.7554/eLife.88573</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.88573.3</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group></article-categories><title-group><article-title>YAP/TAZ enhances P-body formation to promote tumorigenesis</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Shen</surname><given-names>Xia</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Peng</surname><given-names>Xiang</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Guo</surname><given-names>YueGui</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Dai</surname><given-names>Zhujiang</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Cui</surname><given-names>Long</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Yu</surname><given-names>Wei</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-9898-4607</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Liu</surname><given-names>Yun</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-0258-4025</contrib-id><email>liuyun@xinhuamed.com.cn</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Liu</surname><given-names>Chen-Ying</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-8930-6182</contrib-id><email>liuchenying@xinhuamed.com.cn</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0220qvk04</institution-id><institution>Department of Colorectal and Anal Surgery, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</institution></institution-wrap><addr-line><named-content content-type="city">Shanghai</named-content></addr-line><country>China</country></aff><aff id="aff2"><label>2</label><institution>Shanghai Colorectal Cancer Research Center</institution><addr-line><named-content content-type="city">Shanghai</named-content></addr-line><country>China</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/013q1eq08</institution-id><institution>State Key Laboratory of Genetic Engineering, School of Life Sciences, Zhongshan Hospital, Fudan University</institution></institution-wrap><addr-line><named-content content-type="city">Shanghai</named-content></addr-line><country>China</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Yang</surname><given-names>Yongliang</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/023hj5876</institution-id><institution>Dalian University of Technology</institution></institution-wrap><country>China</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Liu</surname><given-names>Caigang</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/032d4f246</institution-id><institution>Shengjing Hospital of China Medical University</institution></institution-wrap><country>China</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>24</day><month>07</month><year>2024</year></pub-date><volume>12</volume><elocation-id>RP88573</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2023-04-29"><day>29</day><month>04</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2023-06-03"><day>03</day><month>06</month><year>2023</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2023.06.02.542626"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2023-08-24"><day>24</day><month>08</month><year>2023</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.88573.1"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-03-04"><day>04</day><month>03</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.88573.2"/></event></pub-history><permissions><copyright-statement>© 2023, Shen, Peng, Guo et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Shen, Peng, Guo et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-88573-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-88573-figures-v1.pdf"/><abstract><p>The role of processing bodies (P-bodies) in tumorigenesis and tumor progression is not well understood. Here, we showed that the oncogenes YAP/TAZ promote P-body formation in a series of cancer cell lines. Mechanistically, both transcriptional activation of the P-body-related genes <italic>SAMD4A, AJUBA</italic>, and <italic>WTIP</italic> and transcriptional suppression of the tumor suppressor gene <italic>PNRC1</italic> are involved in enhancing the effects of YAP/TAZ on P-body formation in colorectal cancer (CRC) cells. By reexpression of PNRC1 or knockdown of P-body core genes (<italic>DDX6, DCP1A,</italic> and <italic>LSM14A</italic>), we determined that disruption of P-bodies attenuates cell proliferation, cell migration, and tumor growth induced by overexpression of YAP<sup>5SA</sup> in CRC. Analysis of a pancancer CRISPR screen database (DepMap) revealed co-dependencies between YAP/TEAD and the P-body core genes and correlations between the mRNA levels of <italic>SAMD4A, AJUBA, WTIP, PNRC1,</italic> and YAP target genes. Our study suggests that the P-body is a new downstream effector of YAP/TAZ, which implies that reexpression of PNRC1 or disruption of P-bodies is a potential therapeutic strategy for tumors with active YAP.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>YAP/TAZ</kwd><kwd>Hippo pathway</kwd><kwd>PNRC1</kwd><kwd>P-body</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>82172916</award-id><principal-award-recipient><name><surname>Liu</surname><given-names>Chen-Ying</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>82073056</award-id><principal-award-recipient><name><surname>Liu</surname><given-names>Yun</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>82273022</award-id><principal-award-recipient><name><surname>Cui</surname><given-names>Long</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100013285</institution-id><institution>Program for Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Liu</surname><given-names>Chen-Ying</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>82372648</award-id><principal-award-recipient><name><surname>Liu</surname><given-names>Chen-Ying</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>P-body is a new downstream effector of YAP/TAZ for tumorigenesis and tumor progression, suggesting disruption of P-bodies as a potential therapeutic strategy for tumors with active YAP.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>The Hippo pathway is an evolutionally conserved signaling pathway that regulates organ size and plays vital roles in development and tissue homeostasis (<xref ref-type="bibr" rid="bib17">Driskill and Pan, 2021</xref>; <xref ref-type="bibr" rid="bib39">Ma et al., 2019</xref>; <xref ref-type="bibr" rid="bib54">Russell and Camargo, 2022</xref>). The transcriptional output of the Hippo pathway is mainly mediated by the YAP/TAZ-TEAD transcription complex. In response to various extracellular or intracellular signals, including cell–cell contact, mechanical force, serum stimulation, cellular stress, and cellular energy status, the YAP/TAZ-TEAD complex modulates target gene expression to respond to environmental cues (<xref ref-type="bibr" rid="bib8">Calvo et al., 2013</xref>; <xref ref-type="bibr" rid="bib43">Misra and Irvine, 2018</xref>; <xref ref-type="bibr" rid="bib71">Yu et al., 2012</xref>; <xref ref-type="bibr" rid="bib75">Zhao et al., 2007</xref>). Although initially identified as transcriptional coactivators, YAP/TAZ can also function as corepressors to inhibit target gene transcription by recruiting the nucleosome remodeling and histone deacetylase (NuRD) complex (<xref ref-type="bibr" rid="bib33">Kim et al., 2015b</xref>). The evidence of Hippo pathway dysregulation in a variety of cancers and the list of YAP/TAZ target genes continue to increase (<xref ref-type="bibr" rid="bib7">Calses et al., 2019</xref>; <xref ref-type="bibr" rid="bib35">Kulkarni et al., 2020</xref>; <xref ref-type="bibr" rid="bib46">Nguyen and Yi, 2019</xref>; <xref ref-type="bibr" rid="bib63">Wang et al., 2018</xref>; <xref ref-type="bibr" rid="bib73">Zanconato et al., 2016</xref>). Dysregulation of YAP/TAZ-TEAD transcriptional output endows tumor cells with every hallmark of cancer, including sustained proliferation, resistance to apoptosis, tumor-promoting inflammation, tumor immune escape, dysregulated tumor metabolism, etc. (<xref ref-type="bibr" rid="bib7">Calses et al., 2019</xref>; <xref ref-type="bibr" rid="bib23">Hanahan, 2022</xref>; <xref ref-type="bibr" rid="bib35">Kulkarni et al., 2020</xref>; <xref ref-type="bibr" rid="bib46">Nguyen and Yi, 2019</xref>; <xref ref-type="bibr" rid="bib73">Zanconato et al., 2016</xref>).</p><p>At the cellular organization level, the YAP/TAZ-TEAD transcription complex modulates mitochondrial fusion; cytoskeleton, primary cilium, and focal adhesion assembly; and caveolae formation (<xref ref-type="bibr" rid="bib32">Kim et al., 2015a</xref>; <xref ref-type="bibr" rid="bib41">Mason et al., 2019</xref>; <xref ref-type="bibr" rid="bib44">Nagaraj et al., 2012</xref>; <xref ref-type="bibr" rid="bib50">Qiao et al., 2017</xref>; <xref ref-type="bibr" rid="bib51">Rausch et al., 2019</xref>). Processing bodies (P-bodies) are cytoplasmic membraneless organelles that consist of ribonucleoprotein complexes (RNPs) and are formed by phase separation (<xref ref-type="bibr" rid="bib38">Luo et al., 2018</xref>; <xref ref-type="bibr" rid="bib52">Riggs et al., 2020</xref>). Although initial studies hypothesized that mRNAs in P-bodies are targeted for decay and translational repression, it was subsequently suggested that P-bodies are not required for mRNA decay and that repressed mRNAs can be recycled from P-bodies to reenter translation; thus, the primary function of P-bodies is controlling the storage of untranslated mRNAs (<xref ref-type="bibr" rid="bib14">Decker and Parker, 2012</xref>; <xref ref-type="bibr" rid="bib26">Hubstenberger et al., 2017</xref>; <xref ref-type="bibr" rid="bib38">Luo et al., 2018</xref>). The role of P-bodies in tumorigenesis and tumor progression is not well studied (<xref ref-type="bibr" rid="bib2">Anderson et al., 2015</xref>; <xref ref-type="bibr" rid="bib36">Lavalée et al., 2021</xref>; <xref ref-type="bibr" rid="bib52">Riggs et al., 2020</xref>). The formation of P-bodies is correlated with epithelial–mesenchymal transition (EMT) in breast cancer (<xref ref-type="bibr" rid="bib24">Hardy et al., 2017</xref>). In contrast, there is also evidence that an increase in P-bodies leads to attenuated growth, migration, and invasion of prostate cancer cells (<xref ref-type="bibr" rid="bib5">Bearss et al., 2021</xref>). Recently, YAP was reported to be a negative regulator of P-bodies and to be involved in Kaposi sarcoma-associated herpesvirus (KHSV)-induced P-body disassembly in human umbilical vein endothelial cells (HUVECs) (<xref ref-type="bibr" rid="bib9">Castle et al., 2021</xref>). However, this regulatory axis and the potential function of P-bodies in YAP-induced tumorigenesis remain unclear.</p><p>In this study, we discovered that YAP/TAZ are enhancers but not negative regulators of P-body formation in a series of cancer cell lines. YAP/TAZ modulates the transcription of multiple P-body-related genes, especially repressing the transcription of the tumor suppressor proline-rich nuclear receptor coactivator 1 (<italic>PNRC1</italic>) through cooperation with the NuRD complex. As a direct YAP/TAZ target gene, PNRC1 functions as a critical effector in YAP-induced biogenesis of P-bodies and tumorigenesis in colorectal cancer (CRC). Furthermore, disruption of P-bodies by knockdown of core component genes of P-bodies attenuated the protumorigenic effects of YAP in CRC. Thus, our study reveals a YAP–P-body positive regulatory axis in CRC, which exposes the vital role of YAP/TAZ in the biogenesis of P-bodies in tumors and implies that reexpression of PNRC1 or disruption of P-bodies is a potential therapeutic strategy for cancers with active YAP.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>YAP/TAZ regulates the transcription of P-body-related genes</title><p>Previously, to identify the new target genes and molecular signatures of YAP/TAZ in CRC, we performed RNA sequencing analysis of HCT116 CRC cells with simultaneous knockdown of YAP and TAZ (GSE176475) (<xref ref-type="bibr" rid="bib22">Guo et al., 2022</xref>). Gene Ontology enrichment analysis of the 674 differentially expressed genes upon knockdown of YAP/TAZ (fold change [FC] &gt; 2, p&lt;0.05) revealed that the genes downregulated by YAP/TAZ knockdown were enriched in the term P-body in the cellular component category (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). We further expanded our analysis to the moderately differentially expressed genes (FC &lt; 0.66 or &gt;1.5) that were annotated as related to P-bodies (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>, <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). Through integration with the public ChIP-seq data for TEAD4 in HCT116 cells from the ENCODE database, <italic>AJUBA, WTIP, NOCT, SAMD4A,</italic> and <italic>PNRC1</italic> were selected for in-depth investigation (<xref ref-type="fig" rid="fig1">Figure 1B</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>). Intriguingly, the public TEAD4 ChIP-seq datasets for the other three cancer cell lines (A549, MCF7, and MDA-MB-231), not just HCT116 cells, also showed strong TEAD4 binding peaks in the genomic loci of these five P-body-related genes (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B</xref>; <xref ref-type="bibr" rid="bib42">Mei et al., 2017</xref>). HCT116, A549, MCF7, and MDA-MB-231 are well-established cell models for exploring YAP/TAZ function and the cell proliferation of these four cell lines is dependent on YAP/TAZ activity (<xref ref-type="bibr" rid="bib53">Rosenbluh et al., 2012</xref>; <xref ref-type="bibr" rid="bib57">Shreberk-Shaked et al., 2020</xref>; <xref ref-type="bibr" rid="bib72">Zanconato et al., 2015</xref>; <xref ref-type="bibr" rid="bib76">Zhu et al., 2019</xref>). It is worth noting that cell contact inhibition was observed in HCT116 and MDA-MB-231 and YAP remains in the nucleus regardless of cell–cell contact in A549 and MCF7 cells (<xref ref-type="bibr" rid="bib19">Fan et al., 2013</xref>; <xref ref-type="bibr" rid="bib31">Kim et al., 2011</xref>; <xref ref-type="bibr" rid="bib37">Lee et al., 2018</xref>; <xref ref-type="bibr" rid="bib67">Wu et al., 2019</xref>). The ChIP–qPCR results in HCT116 cells further confirmed that TEAD4 bound to the promoter regions of <italic>AJUBA, WTIP, NOCT, SAMD4A,</italic> and <italic>PNRC1</italic> and to the intronic region of <italic>PNRC1</italic> (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). Next, we confirmed the significantly downregulated mRNA expression of <italic>AJUBA, WTIP, SAMD4A,</italic> and <italic>NOCT</italic> and moderately increased expression of <italic>PNRC1</italic> in YAP/TAZ knockdown HCT116 cells by qPCR analysis; this pattern was also observed in A549 lung cancer cells and MDA-MB-231 breast cancer cells (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). Consistent with these findings, overexpression of the constitutively active YAP<sup>5SA</sup> mutant but not the TEAD binding-defective YAP<sup>5SA-S94A</sup> mutant significantly decreased the mRNA level of <italic>PNRC1</italic> and increased the mRNA level of <italic>SAMD4A</italic> in HCT116, MCF7 and A549 cells (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). Enhanced expression of <italic>AJUBA</italic> and <italic>WTIP</italic> was observed in HCT116 and MCF7 cells but not in A549 cells (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). Since <italic>NOCT</italic> was not affected by overexpression of YAP<sup>5SA</sup> in either MCF7 or A549 cells, we did not investigate <italic>NOCT</italic> in subsequent functional experiments (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). Finally, we confirmed that the protein level of PNRC1 was increased by knockdown of YAP/TAZ in HCT116 cells (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C</xref>). Additionally, overexpression of YAP<sup>5SA</sup> but not YAP<sup>5SA-S94A</sup> decreased the protein level of PNRC1 in HCT116, A549, and MDA-MB-231 cells (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1D</xref>). Overall, these data demonstrate that YAP/TAZ modulates the transcription of P-body-related genes through the TEAD transcription factors.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>YAP/TAZ transcriptionally regulates genes related to P-bodies.</title><p>(<bold>A</bold>) Gene Ontology (GO) analysis of the downregulated genes upon knockdown of <italic>YAP/TAZ</italic> in HCT116 cells. The graph shows enrichment in the cellular component category. (<bold>B</bold>) ChIP–qPCR analysis of endogenous TEAD4 binding to the genomic locus of the indicated P-body-related genes in HCT116 cells. The <italic>CTGF</italic> promoter was included as the positive control. (<bold>C</bold>) qPCR analysis of the mRNA levels of the indicated P-body-related genes in <italic>YAP/TAZ</italic> knockdown HCT116, MDA-MB-231, and A549 cells. Cells were transfected with <italic>YAP/TAZ</italic> siRNA for 3 d before qPCR analysis. (<bold>D</bold>) qPCR analysis of the mRNA levels of the indicated P-body-related genes in HCT116, MCF7, and A549 cells stably expressing YAP<sup>5SA</sup> and YAP<sup>5SA-S94A</sup>. Cells were infected with <italic>YAP<sup>5SA</sup></italic>- and <italic>YAP<sup>5SA-S94A</sup></italic>-containing retroviruses and selected with puromycin for 1 wk before qPCR analysis. n = 3 biologically independent samples per group. Two-tailed Student’s <italic>t</italic>-test (<bold>B</bold>) and one-way ANOVA (<bold>C, D</bold>) were performed to assess statistical significance in this figure. These data (<bold>B–D</bold>) are representative of three independent experiments.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Original data for the statistical analysis in <xref ref-type="fig" rid="fig1">Figure 1B–D</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-88573-fig1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-88573-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>RNA-seq and ChIP-seq analysis of YAP/TEAD’s target genes related to P-bodies.</title><p>(<bold>A</bold>) Heatmap showing the mRNA levels of 76 genes annotated as P-body-related genes, as detected in HCT116 cells by RNA-seq (GSE176475). (<bold>B</bold>) Representative sequencing TEAD4 ChIP-seq tracks at the <italic>SAMD4A/AJUBA/WTIP/NCOT/PNRC1</italic> loci in HCT-116, A549, MDA-MB-231, and MCF7 cells. The ChIP-seq data were extracted from the Cistrome database and uploaded to the UCSC Genome Browser for visualization. (<bold>C</bold>) Western blot analysis of PNRC1, YAP, and TAZ in control and <italic>YAP/TAZ</italic> knockdown HCT116 cells. (<bold>D</bold>) Western blot analysis of PNRC1, YAP, and FLAG in control HCT116 cells and HCT116 cells overexpressing FLAG-YAP<sup>5SA</sup> and YAP<sup>5SA-S94A</sup>. These data (<bold>C, D</bold>) are representative of two independent experiments.</p><p><supplementary-material id="fig1s1sdata1"><label>Figure 1—figure supplement 1—source data 1.</label><caption><title>Original data for the heat map in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-88573-fig1-figsupp1-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig1s1sdata2"><label>Figure 1—figure supplement 1—source data 2.</label><caption><title>Original file for the Western blot analysis in <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C and D</xref>.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-88573-fig1-figsupp1-data2-v1.pdf"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-88573-fig1-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-2"><title>YAP/TAZ enhances P-body formation</title><p>In contrast to stress granule (SG) formation, P-body formation is constitutive and independent of the activation of the integrated stress response (ISR) (<xref ref-type="bibr" rid="bib38">Luo et al., 2018</xref>; <xref ref-type="bibr" rid="bib52">Riggs et al., 2020</xref>). DEAD-box ATP-dependent RNA helicase 6 (DDX6) and mRNA-decapping enzyme 1A (DCP1A) are the essential components of P-bodies and are normally used as the biomarkers for P-bodies (<xref ref-type="bibr" rid="bib27">James et al., 2010</xref>; <xref ref-type="bibr" rid="bib36">Lavalée et al., 2021</xref>; <xref ref-type="bibr" rid="bib38">Luo et al., 2018</xref>). To explore whether YAP/TAZ regulates P-body formation, we performed immunofluorescence analysis of DDX6 and DCP1A in YAP/TAZ knockdown cells plated at a low density. We found that knockdown of YAP/TAZ significantly decreased but overexpression of YAP<sup>5SA</sup> increased the number of DDX6/DCP1A-positive foci in HCT116 cells (<xref ref-type="fig" rid="fig2">Figure 2A and B</xref>). HCT116 cells expressing YAP<sup>5SA-S94A</sup> and control HCT116 cells showed similar numbers of P-bodies, which indicated that the TEAD transcription factors mediate the enhanced effects of YAP/TAZ on P-body formation (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). Similar results were observed in YAP/TAZ knockdown MDA-MB-231 cells and YAP<sup>5SA</sup>/YAP<sup>5SA-S94A</sup>-expressing A549 cells (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A and B</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>YAP/TAZ promotes P-body formation in colorectal cancer (CRC) cells.</title><p>(<bold>A</bold>) Immunofluorescence analysis of the P-body markers DDX6 and DCP1A in <italic>YAP/TAZ</italic> knockdown HCT116 cells. Cells were transfected with <italic>YAP/TAZ</italic> siRNA for 3 d before processing for immunofluorescence staining using anti-DDX6 and anti-DCP1A antibodies. Foci were counted in 100 cells per group. (<bold>B</bold>) Immunofluorescence analysis of DDX6 and DCP1A in HCT116 cells expressing YAP<sup>5SA</sup> and YAP<sup>5SA-S94A</sup>. (<bold>C</bold>) Immunofluorescence analysis of DDX6 and DCP1A in HCT116 cells. Cells were treated with 10% fetal bovine serum (FBS) for 1 hr after overnight serum starvation (SS). (<bold>D</bold>) Immunofluorescence analysis of DDX6 and DCP1A in HCT116 cells in sparse or confluent culture. (<bold>E, F</bold>) qPCR analysis of the indicated genes in HCT116 cells. HCT116 cells were treated with 10% FBS for 1 hr after overnight SD (<bold>E</bold>) or culture under sparse or confluent conditions in standard culture medium (<bold>F</bold>). Kruskal–Wallis test (<bold>A, B</bold>), Mann–Whitney <italic>U</italic> test (<bold>C, D</bold>), and two-tailed Student’s <italic>t</italic>-test (<bold>E, F</bold>) were performed to assess statistical significance. These data (<bold>A–F</bold>) are representative of three independent experiments.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Original data for the statistical analysis in <xref ref-type="fig" rid="fig2">Figure 2A–F</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-88573-fig2-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-88573-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>YAP/TAZ modulates P-body formation in breast, lung and colorectal cancer cells.</title><p>(<bold>A</bold>) Immunofluorescence analysis of the P-body markers DDX6 and DCP1A in <italic>YAP/TAZ</italic> knockdown MDA-MB-231 cells. Cells were transfected with <italic>YAP/TAZ</italic> siRNA for 3 d before processing for immunofluorescence staining using anti-DDX6 and anti-DCP1A antibodies. Foci were counted in 100 cells per group. (<bold>B</bold>) Immunofluorescence analysis of DDX6 and DCP1A in A549 cells expressing YAP<sup>5SA</sup> and YAP<sup>5SA-S94A</sup>. (<bold>C</bold>) Immunofluorescence analysis of DDX6 and DCP1A in HCT116 cells. Cells were transfected with control and <italic>YAP/TAZ</italic> siRNA for 3 d before overnight serum starvation. Then, the starved cells were treated with 10% fetal bovine serum (FBS) for 1 hr before immunofluorescence staining. Kruskal–Wallis test was performed to assess statistical significance. These data (<bold>A–C</bold>) are representative of three independent experiments.</p><p><supplementary-material id="fig2s1sdata1"><label>Figure 2—figure supplement 1—source data 1.</label><caption><title>Original data for the statistical analysis in <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A–C</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-88573-fig2-figsupp1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-88573-fig2-figsupp1-v1.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>YAP/TAZ modulates P-body formation in untransformed NIH3T3 cells.</title><p>(<bold>A</bold>) Immunofluorescence analysis of DDX6 and LSM14A in NIH3T3 cells expressing YAP<sup>5SA</sup> and YAP<sup>5SA-S94A</sup>. Foci were counted in 100 cells per group. (<bold>B</bold>) Immunofluorescence analysis of DDX6 and LSM14A in NIH3T3 cells. Sparse cells were treated with 10% fetal bovine serum (FBS) for 1 hr after overnight serum starvation (SS). (<bold>C</bold>) Immunofluorescence analysis of DDX6 and LSM14A in NIH3T3 cells in sparse or confluent culture. (<bold>D</bold>) Immunofluorescence analysis of DDX6 and LSM14A in NIH3T3 cells cultured on soft (1 kPa) to stiff (40 kPa) matrices. (<bold>E–H</bold>) qPCR analysis of the indicated genes in NIH3T3 cells expressing YAP<sup>5SA</sup> and YAP<sup>5SA-S94A</sup> (<bold>E</bold>) or NIH3T3 cells treated with 10% FBS for 1 hr after overnight SS (<bold>F</bold>) or cultured under sparse or confluent conditions in standard culture medium (<bold>G</bold>) or cultured on soft (1 kPa) to stiff (40 kPa) matrices (<bold>H</bold>). Kruskal–Wallis test (<bold>A</bold>), Mann–Whitney <italic>U</italic> test (<bold>B–D</bold>), one-way ANOVA (<bold>E</bold>), and two-tailed Student’s <italic>t</italic>-test (<bold>F–H</bold>) were performed to assess statistical significance. These data (<bold>A–H</bold>) are representative of three independent experiments.</p><p><supplementary-material id="fig2s2sdata1"><label>Figure 2—figure supplement 2—source data 1.</label><caption><title>Original data for the statistical analysis in <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2A–H</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-88573-fig2-figsupp2-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-88573-fig2-figsupp2-v1.tif"/></fig></fig-group><p>YAP/TAZ are well known to be activated by serum stimulation and suppressed by high cell densities (<xref ref-type="bibr" rid="bib71">Yu et al., 2012</xref>; <xref ref-type="bibr" rid="bib75">Zhao et al., 2007</xref>). Of note, cytoplasmic translocation of YAP at high cell density was first observed in the untransformed NIH3T3 cells (<xref ref-type="bibr" rid="bib75">Zhao et al., 2007</xref>). Thus, in addition to a series of cancer cell lines, NIH3T3 cells were further included in this study. Consistently, overexpression of YAP<sup>5SA</sup> but not the YAP<sup>5SA-S94A</sup> increased the number of DDX6/LSM14A-positive foci in NIH3T3 cells (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2A</xref>). Upregulation of <italic>Ajuba, Samd4</italic> (mouse ortholog of human SAMD4A) and <italic>Noct</italic> and downregulation of <italic>Pnrc1</italic> was also observed in NIH3T3 cells overexpressed with YAP<sup>5SA</sup> but not cells with YAP<sup>5SA-S94A</sup> overexpression (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2E</xref>). Moreover, despite their constitutive formation in cells, the size and number of P-bodies are altered in response to stress (<xref ref-type="bibr" rid="bib38">Luo et al., 2018</xref>; <xref ref-type="bibr" rid="bib52">Riggs et al., 2020</xref>). Next, we evaluated P-bodies under exposure to different stimuli. We observed that serum stimulation led to rapid induction of P-body formation in HCT116 and NIH3T3 cells (<xref ref-type="fig" rid="fig2">Figure 2C</xref>, <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2B</xref>). Knockdown of YAP/TAZ attenuated the enhancement of P-body formation induced by serum stimulation (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1C</xref>). Conversely, at a high cell density, the number of P-bodies was significantly decreased in HCT116 and NIH3T3 cells (<xref ref-type="fig" rid="fig2">Figure 2D</xref>, <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2C</xref>). Consistent with this finding, the expression of <italic>SAMD4A</italic>, <italic>NOCT</italic>, and <italic>WTIP</italic> in HCT116 cells was induced by serum stimulation and suppressed by culture at a high cell density (<xref ref-type="fig" rid="fig2">Figure 2E and F</xref>). Similar results were also observed in NIH3T3 cells (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2F and G</xref>). Intriguingly, both serum starvation and culture at a high cell density dramatically increased the expression of <italic>PNRC1</italic>, consistent with the tumor suppressor function of PNRC1 (<xref ref-type="fig" rid="fig2">Figure 2E and F</xref>, <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2F and G</xref>). Recent studies have revealed that mechanical cues as an important signal modulating YAP/TAZ activity (<xref ref-type="bibr" rid="bib3">Aragona et al., 2013</xref>; <xref ref-type="bibr" rid="bib18">Dupont et al., 2011</xref>). Diverse mechanical forces, such as increased extracellular matrix (ECM) rigidity, cell stretching, shear stress, or the increased area of cell adhesion, can all activate YAP, which is dominant over Hippo signaling (<xref ref-type="bibr" rid="bib13">Dasgupta and McCollum, 2019</xref>; <xref ref-type="bibr" rid="bib49">Piccolo et al., 2014</xref>). Next, we examined whether ECM stiffness affected P-body formation. When NIH3T3 cells were shifted from soft (1 kPa) to stiff (40 kPa) matrices, YAP was translocated into nucleus and activated (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2D</xref>). Furthermore, the P-body formation was enhanced, which was associated with decreased mRNA level of <italic>Pnrc1</italic> and increased mRNA levels of <italic>Ajuba, Samd4,</italic> and <italic>Noct</italic> (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2D and H</xref>). Collectively, our data indicate that YAP/TAZ could be positive regulators of P-body formation in response to various stimuli, probably by modulating the expression of P-body-related genes.</p></sec><sec id="s2-3"><title>SAMD4A, AJUBA, and PNRC1 mediate the functions of YAP/TAZ in regulating P-body formation</title><p>Next, we investigated whether the P-body-related genes transcriptionally regulated by YAP/TAZ mediate the biological functions of YAP/TAZ in regulating P-body formation. The LIM-domain proteins AJUBA, WTIP, and LIMD1 are known as negative regulators of LATS1 (<xref ref-type="bibr" rid="bib12">Das Thakur et al., 2010</xref>). They are also components of P-bodies and are required for miRNA-mediated silencing (<xref ref-type="bibr" rid="bib27">James et al., 2010</xref>). SAMD4A is the mammalian homolog of <italic>Drosophila</italic> Smaug, which is involved in translational repression and localized in P-bodies (<xref ref-type="bibr" rid="bib4">Baez and Boccaccio, 2005</xref>). First, we knocked down <italic>AJUBA</italic> and <italic>SAMD4A</italic> in HCT116 cells overexpressing YAP<sup>5SA</sup> (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A and B</xref>). As expected, knockdown of both <italic>AJUBA</italic> and <italic>SAMD4A</italic> significantly diminished the promoting effect of YAP<sup>5SA</sup> overexpression on P-body formation in HCT116 cells (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). Unlike AJUBA and SAMD4A, PNRC1 is a tumor suppressor that inhibits P-body formation by recruiting cytoplasmic DCP1A/DCP2 into the nucleolus, thus loss of cytoplasmic DCP1A/DCP2 results in disruption of P-body (<xref ref-type="bibr" rid="bib20">Gaviraghi et al., 2018</xref>). Overexpression of YAP<sup>5SA</sup> suppressed PNRC1 expression; thus, WT PNRC1 and PNRC1 with the W300A mutation, which disrupts the interaction between PNRC1 and DCP1A/DCP2, were overexpressed in YAP<sup>5SA</sup>-expressing HCT116 cells (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1C and D</xref>; <xref ref-type="bibr" rid="bib20">Gaviraghi et al., 2018</xref>). We observed that overexpression of WT PNRC1 but not the W300A mutant dramatically decreased the number of P-bodies in YAP<sup>5SA</sup>-expressing HCT116 cells (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). We also examined whether the attenuation of P-body formation by knockdown of YAP/TAZ can be restored by knockdown of <italic>PNRC1</italic> (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1E</xref>). Consistent with the above findings, the reduction in the P-body number was reversed by knockdown of <italic>PNRC1</italic> in YAP/TAZ knockdown HCT116 cells (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1F</xref>). Collectively, these findings indicate that YAP/TAZ enhances P-body formation through modulation of a series of P-body-related genes. Both activation of SAMD4A and AJUBA expression and downregulation of PNRC1 are involved in YAP/TAZ-induced P-body formation.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>SAMD4A, AJUBA, and PNRC1 mediate the regulatory functions of YAP/TAZ in P-body formation.</title><p>(<bold>A</bold>) Immunofluorescence analysis of DDX6 and DCP1A in HCT116 cells stably expressing YAP<sup>5SA</sup> and YAP<sup>5SA</sup>-expressing cells transiently transfected with <italic>SMAD4A</italic> and <italic>AJUBA</italic> siRNA. Foci were counted in 100 cells per group. (<bold>B</bold>) Immunofluorescence analysis of DDX6 and DCP1A in HCT116 cells expressing YAP<sup>5SA</sup> alone or in combination with PNRC1<sup>WT</sup> or PNRC1<sup>W300A</sup>. Kruskal–Wallis test was performed to assess statistical significance. These data (<bold>A–B</bold>) are representative of three independent experiments.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Original data for the statistical analysis in <xref ref-type="fig" rid="fig3">Figure 3A and B</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-88573-fig3-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-88573-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Knockdown of <italic>PNRC1</italic> reverses the attenuated P-body formation induced by <italic>YAP/TAZ</italic> knockdown.</title><p>(<bold>A, B</bold>) qPCR analysis of the mRNA levels of <italic>SAMD4A</italic> (<bold>A</bold>) and <italic>AJUBA</italic> (<bold>B</bold>) in HCT116 cells stably expressing FLAG-YAP<sup>5SA</sup> and YAP<sup>5SA</sup> and transfected with <italic>SMAD4A</italic> or <italic>AJUBA</italic> siRNA. n = 3 biologically independent samples per group. (<bold>C, D</bold>) qPCR (<bold>C</bold>) and western blot (<bold>D</bold>) analysis of PNRC1 expression in HCT116 cells stably expressing FLAG-YAP<sup>5SA</sup> alone or in combination with PNRC1<sup>WT</sup> or PNRC1<sup>W300A</sup>. (<bold>E</bold>) qPCR analysis of the mRNA level of <italic>PNRC1/YAP/TAZ</italic> in <italic>YAP/TAZ</italic> knockdown HCT116 cells transfected with PNRC1 siRNA. n = 3 biologically independent samples per group. (<bold>F</bold>) Immunofluorescence analysis of DCP1A in <italic>YAP/TAZ</italic> knockdown HCT116 cells transfected with <italic>PNRC1</italic> siRNA. Foci were counted in 100 cells per group. One-way ANOVA (<bold>A–C, E</bold>) and Kruskal–Wallis test (<bold>F</bold>) were performed to assess statistical significance for qPCR analysis in this figure. The data (<bold>F</bold>) is representative of two independent experiments.</p><p><supplementary-material id="fig3s1sdata1"><label>Figure 3—figure supplement 1—source data 1.</label><caption><title>Original data for the statistical analysis in <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A–F</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-88573-fig3-figsupp1-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig3s1sdata2"><label>Figure 3—figure supplement 1—source data 2.</label><caption><title>Original file for the western blot analysis in <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1D</xref>.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-88573-fig3-figsupp1-data2-v1.pdf"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-88573-fig3-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-4"><title>YAP/TAZ inhibit PNRC1 gene transcription by recruiting the NuRD complex</title><p>PNRC1 is a newly identified tumor suppressor gene whose expression is frequently downregulated in cancer (<xref ref-type="bibr" rid="bib20">Gaviraghi et al., 2018</xref>). Thus, we further explored the molecular mechanism of YAP/TAZ in inhibiting the <italic>PNRC1</italic> gene transcription. The ChIP-seq data for TEAD4 at the <italic>PNRC1</italic> gene locus in multiple cancer cells implicated PNRC1 as a potential direct target gene of YAP/TAZ-TEAD transcription complexes (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B</xref>). As ChIP–qPCR analysis of TEAD4 in HCT116 cells revealed one TEAD4 binding site at the <italic>PNRC1</italic> promoter and another in the <italic>PNRC1</italic> intron, we constructed <italic>PNRC1</italic> promoter and <italic>PNRC1</italic> intron luciferase reporter plasmids. We observed that overexpression of YAP<sup>5SA</sup> significantly decreased the luciferase activity of both the <italic>PNRC1</italic> promoter and intron reporters (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). Compared with the 5SA mutation in YAP, the S94A mutation resulted in a decreased suppressive effect on <italic>PNRC1</italic> promoter and intron luciferase reporter activity (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). In contrast, the luciferase activity of both the <italic>PNRC1</italic> promoter and intron reporters was significantly enhanced in <italic>YAP/TAZ</italic> knockdown HCT116 cells (<xref ref-type="fig" rid="fig4">Figure 4B</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>). Bioinformatic analysis of TEAD4 ChIP peaks in the <italic>PNRC1</italic> promoter and intronic regions with JASPAR revealed the existence of one TEAD binding motif in each peak region; thus, we further constructed <italic>PNRC1</italic> luciferase reporter plasmids with mutated TEAD binding sites. Consistent with the above results, mutation of the TEAD binding sites abolished the inhibitory effect of YAP<sup>5SA</sup>on the <italic>PNRC1</italic> promoter and intron luciferase reporters (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). Similarly, mutation of the TEAD binding sites escaped the derepression of <italic>PNRC1</italic> promoter and intron luciferase reporters by <italic>YAP/TAZ</italic> knockdown (<xref ref-type="fig" rid="fig4">Figure 4D</xref>). Furthermore, the ChIP–qPCR results confirmed that YAP bound to the promoter and intronic regions of <italic>PNRC1</italic>, which required its interaction with TEADs (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B and C</xref>).</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>YAP suppresses PNRC1 gene transcription by recruiting the NuRD complex.</title><p>(<bold>A</bold>) Overexpression of YAP<sup>5SA</sup> but not YAP<sup>5SA-S94A</sup> decreased the luciferase activity of the <italic>PNRC1</italic> promoter and intron reporters. HEK-293T cells were transfected with the indicated FLAG-<italic>YAP<sup>5SA</sup></italic> and <italic>YAP<sup>5SA-S94A</sup></italic> expression plasmids and the <italic>PNRC1</italic> promoter or intron luciferase reporter. (<bold>B</bold>) Knockdown of <italic>YAP/TAZ</italic> stimulated the luciferase activity of the <italic>PNRC1</italic> promoter and intron reporters. The <italic>PNRC1</italic> promoter or intron luciferase reporter plasmid and the Renilla luciferase reporter plasmid were co-transfected into HCT116 cells stably expressing pLKO-vec, sh<italic>YAP/TAZ</italic>-1, or sh<italic>YAP/TAZ</italic>-2. (<bold>C, D</bold>) Luciferase assay of the <italic>PNRC1</italic> promoter/intron WT reporters and mutant reporters with TEAD binding motif mutations in HEK-293T cells (<bold>C</bold>) and HCT116 cells (<bold>D</bold>). (<bold>E</bold>) ChIP–qPCR analysis of CHD4 binding to the <italic>PNRC1</italic> promoter and intronic regions in control and HCT116 cells stably expressing FLAG-YAP<sup>5SA</sup> or YAP<sup>5SA-S94A</sup>. (<bold>F</bold>) qPCR analysis of <italic>PNRC1, CHD4,</italic> and <italic>RBBP4</italic> in HCT116 cells transfected with the indicated siRNAs. n = 3 biologically independent samples per group. One-way ANOVA (<bold>A–E</bold>) and two-tailed Student’s <italic>t</italic>-test (<bold>F</bold>) were performed to assess statistical significance in this figure. These data (<bold>A–F</bold>) are representative of two independent experiments.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Original data for the statistical analysis in <xref ref-type="fig" rid="fig4">Figure 4A–F</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-88573-fig4-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-88573-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>TEADs and CHD4 mediates YAP-dependent inhibition on <italic>PNRC1</italic> gene transcription.</title><p>(<bold>A</bold>) qPCR and western blot analysis of the YAP/TAZ knockdown stable HCT116 cells. (<bold>B</bold>) ChIP–qPCR analysis of FLAG-YAP<sup>5SA</sup>, YAP<sup>5SA-S94A</sup> binding to the <italic>PNRC1</italic> promoter and intronic regions in control and HCT116 cells stably expressing FLAG-YAP<sup>5SA</sup> or YAP<sup>5SA-S94A</sup>. (<bold>C</bold>) ChIP–qPCR analysis of YAP binding to the genomic locus of the indicated P-body-related genes in control and HCT116 cells with stably knockdown of <italic>TEAD1/3/4</italic>. (<bold>D</bold>) ChIP–qPCR analysis of CHD4 binding to the YAP binding sites of indicated genes in control and HCT116 cells stably expressing FLAG-YAP<sup>5SA</sup> or YAP<sup>5SA-S94A</sup>. One-way ANOVA was performed to assess statistical significance for qPCR analysis in this figure. These data (<bold>B–D</bold>) are representative of two independent experiments. (<bold>E</bold>) Immunofluorescence analysis of DDX6 and DCP1A in HCT116 cells. Cells were transfected with control and <italic>CHD4</italic> siRNA for 3 d before Immunofluorescence analysis. Foci were counted in 100 cells per group. Kruskal–Wallis test was performed to assess statistical significance.</p><p><supplementary-material id="fig4s1sdata1"><label>Figure 4—figure supplement 1—source data 1.</label><caption><title>Original data for the statistical analysis in <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A–E</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-88573-fig4-figsupp1-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig4s1sdata2"><label>Figure 4—figure supplement 1—source data 2.</label><caption><title>Original file for the western blot analysis in <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-88573-fig4-figsupp1-data2-v1.pdf"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-88573-fig4-figsupp1-v1.tif"/></fig></fig-group><p>In addition to functioning as transcriptional coactivators, YAP/TAZ can also act as transcriptional corepressors by recruiting the NuRD complex (<xref ref-type="bibr" rid="bib33">Kim et al., 2015b</xref>). The ChIP–qPCR results showed that the NuRD complex component CHD4 was recruited to the promoter and intronic regions of the <italic>PNRC1</italic> gene by overexpressed YAP<sup>5SA</sup> but not by the TEAD binding-defective YAP<sup>5SA-S94A</sup> mutant (<xref ref-type="fig" rid="fig4">Figure 4E</xref>). Compared to the genomic locus of <italic>PNRC1</italic>, the binding enrichment of CHD4 at the YAP target genes activated by YAP/TAZ was relatively lower and not affected by overexpression of YAP (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1D</xref>). Moreover, knockdown of the NuRD complex components CHD4 and RBBP4 significantly upregulated the mRNA expression of <italic>PNRC1</italic> in HCT116 cells (<xref ref-type="fig" rid="fig4">Figure 4F</xref>). Consistently, knockdown of <italic>CHD4</italic> significantly decreased the number of DDX6/DCP1A-positive foci in HCT116 cells (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1E</xref>). Taken together, these data demonstrate that YAP/TAZ inhibits <italic>PNRC1</italic> gene transcription through direct binding of TEADs to the PNRC1 gene locus and that the NuRD complex is required for the transcriptional repression of <italic>PNRC1</italic> by YAP/TAZ.</p></sec><sec id="s2-5"><title>PNRC1 suppresses the oncogenic function of YAP in CRC</title><p>Analysis of colorectal (COAD) and rectal (READ) TCGA datasets revealed that the mRNA level of PNRC1 was significantly decreased in CRC (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A</xref>). We further confirmed the decreased mRNA level of <italic>PNRC1</italic> in CRC by qPCR analysis of 16 CRC tissues with paired normal mucosal tissues; this finding implies that PNRC1 is a potential tumor suppressor also in CRC (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1B</xref>). Thus, we sought to explore whether downregulation of PNRC1 mediates the oncogenic function of YAP in CRC. To this end, we examined whether the YAP overexpression-induced oncogenic phenotype can be attenuated by coexpression of YAP<sup>5SA</sup> with WT PNRC1 or the W300A mutant in HCT116 cells. We observed that reexpression of WT PNRC1 almost completely abolished the increases in cell proliferation and colony formation induced by YAP<sup>5SA</sup> overexpression in HCT116 cells (<xref ref-type="fig" rid="fig5">Figure 5A and B</xref>). Re-expression of the PNRC1 W300A mutant did not affect the proliferation and colony formation of YAP<sup>5SA</sup>-expressing HCT116 cells, which implied that the suppressive effect of PNRC1 on YAP relies on the recruitment of cytoplasmic DCP1A/DCP2 into the nucleolus by PNRC1 (<xref ref-type="fig" rid="fig5">Figure 5A and B</xref>). Similarly, overexpression of PNRC1 WT but not PNRC1 W300A suppressed the increase in migration induced by YAP<sup>5SA</sup> in HCT116 cells (<xref ref-type="fig" rid="fig5">Figure 5C</xref>). To verify the tumor-suppressive effect of PNRC1 on YAP in CRC in vivo, we performed a xenograft assay by subcutaneously injecting HCT116 cells into nude mice. Consistent with the above findings, reexpression of WT PNRC1 but not the W300A mutant dramatically inhibited the growth of YAP<sup>5SA</sup>-expressing HCT116 xenografts, and xenograft tumors formed from HCT116 cells coexpressing YAP<sup>5SA</sup> and PNRC1 were significantly smaller than the tumors formed from HCT116 cells expressing YAP<sup>5SA</sup> alone or in combination with the PNRC1 W300A mutant (<xref ref-type="fig" rid="fig5">Figure 5D</xref>). Ki67 staining of xenograft tumors further showed fewer Ki67-positive cells in xenograft tumors formed from HCT116 cells coexpressing YAP<sup>5SA</sup> and PNRC1 (<xref ref-type="fig" rid="fig5">Figure 5E</xref>, <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1C</xref>). Next, we examined whether the <italic>YAP/TAZ</italic> knockdown-induced attenuation of the oncogenic phenotype can be restored by knockdown of <italic>PNRC1</italic> in HCT116 cells. Intriguingly, the decrease in proliferation and attenuation of migration induced by <italic>YAP/TAZ</italic> knockdown were reversed by knockdown of <italic>PNRC1</italic> in HCT116 cells (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1D and E</xref>). Overall, these results indicate that YAP promotes tumorigenesis by downregulating PNRC1 expression and that reexpression of PNRC1 suppresses YAP-driven tumor growth.</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>PNRC1 attenuates the oncogenic function of YAP in colorectal cancer (CRC).</title><p>(<bold>A</bold>) CCK8 proliferation assays of HCT116 cells stably expressing YAP<sup>5SA</sup> alone or in combination with of PNRC1<sup>WT</sup> or PNRC1<sup>W300A</sup>. n = 4 biologically independent samples per group. (<bold>B, C</bold>) Colony formation assay (<bold>B</bold>) and Transwell assay (<bold>C</bold>) of HCT116 cells stably expressing YAP<sup>5SA</sup> alone or in combination with PNRC1<sup>WT</sup> or PNRC1<sup>W300A</sup>. n = 3 biologically independent samples per group. (<bold>D</bold>) Representative images of xenograft tumors formed from HCT116 cells stably expressing YAP5SA alone or in combination with of PNRC1<sup>WT</sup> or PNRC1<sup>W300A</sup> (n = 6). (<bold>E</bold>) Representative images of IHC staining of the proliferation marker Ki67 in xenograft tumors formed from HCT-116 cells stably expressing YAP<sup>5SA</sup> alone or in combination with PNRC1<sup>WT</sup> or PNRC1<sup>W300A</sup> (n = 3). Two-way ANOVA (<bold>A</bold>) and one-way ANOVA (<bold>B–E</bold>) were performed to assess statistical significance in this figure. These data (<bold>A–C</bold>) are representative of two independent experiments.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Original data for the statistical analysis in <xref ref-type="fig" rid="fig5">Figure 5A–E</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-88573-fig5-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-88573-fig5-v1.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title><italic>PNRC1</italic> is a tumor suppressor gene in CRC.</title><p>(<bold>A</bold>) Downregulated mRNA expression of PNRC1 in colon cancer (COAD) and rectal cancer (READ) colorectal cancer (CRC) datasets in TCGA. The mRNA levels of <italic>PNRC1</italic> were extracted from the GEPIA database. (<bold>B</bold>) qPCR analysis of the mRNA levels of <italic>PNRC1</italic> in 16 paired normal mucosa and colorectal tumor tissues. Paired Student’s <italic>t</italic>-test was performed to assess statistical significance. (<bold>C</bold>) Representative images of IHC staining of PNRC1 in xenograft tumors formed from HCT116 cells stably expressing YAP<sup>5SA</sup> alone or in combination with PNRC1<sup>WT</sup> or PNRC1<sup>W300A</sup> (n = 3). (<bold>D, E</bold>) CCK8 proliferation assay (n = 4) (<bold>D</bold>) and Transwell migration assay (n = 3) (<bold>E</bold>) of YAP/TAZ knockdown HCT116 cells transfected with <italic>PNRC1</italic> siRNA. One-way ANOVA (<bold>A, C, E</bold>) and two-way ANOVA (<bold>D</bold>) were performed to assess statistical significance. These data (<bold>D, E</bold>) are representative of three independent experiments.</p><p><supplementary-material id="fig5s1sdata1"><label>Figure 5—figure supplement 1—source data 1.</label><caption><title>Original data for the statistical analysis in <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1B–E</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-88573-fig5-figsupp1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-88573-fig5-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-6"><title>P-body disassembly attenuates YAP-driven cell proliferation and migration in CRC</title><p>Due to the inhibitory effects of PNRC1 on P-body formation and the YAP-induced oncogenic phenotype, we evaluated whether enhanced P-body formation plays a vital role in YAP-driven cancer cell proliferation and migration. The proteins LSM14 homolog A (LSM14A) and DDX6 are essential nucleating proteins for P-body assembly, and DCP1A plays a vital role in further RNP aggregation, which is required for stress-dependent P-body aggregation (<xref ref-type="bibr" rid="bib36">Lavalée et al., 2021</xref>; <xref ref-type="bibr" rid="bib38">Luo et al., 2018</xref>; <xref ref-type="bibr" rid="bib52">Riggs et al., 2020</xref>). To explore the requirement of P-body formation for the YAP-induced oncogenic phenotype, we generated YAP<sup>5SA</sup>-expressing HCT116 cell lines with stable knockdown of <italic>DCP1A, LSM14A,</italic> and <italic>DDX6</italic> (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A</xref>, <xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2A–C</xref>). By immunofluorescence analysis of DDX6 and DCP1A, we further confirmed the knockdown of DCP1A and DDX6 and observed a reduced number of P-bodies upon knockdown of DCP1A, LSM14A or DDX6 in YAP<sup>5SA</sup>-expressing HCT116 cells (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1B</xref>). Next, by using a CCK8 assay, we found that knockdown of <italic>DCP1A</italic>, <italic>LSM14A,</italic> and <italic>DDX6</italic> suppressed the proliferation of YAP<sup>5SA</sup>-expressing and control ‘parental’ HCT116 cells, consistent with the results of the colony formation assay (<xref ref-type="fig" rid="fig6">Figure 6A and B</xref>). As an oncogene, YAP is known to promote cell division and inhibit cell apoptosis of cancer cells (<xref ref-type="bibr" rid="bib25">He et al., 2020</xref>; <xref ref-type="bibr" rid="bib28">Jang et al., 2017</xref>). By analyzing the cell cycle and cell apoptosis, we further found that knockdown of <italic>DCP1A, LSM14A,</italic> and <italic>DDX6</italic> all led to downregulation of cell mitosis and increased cell apoptosis, which was opposite to the effect of YAP<sup>5SA</sup> overexpression in HCT116 cells (<xref ref-type="fig" rid="fig6s3">Figure 6—figure supplement 3A and B</xref>). Furthermore, knockdown of either <italic>DCP1A</italic> or <italic>LSM14A</italic> significantly attenuated the enhancement of cell migration induced by overexpression of YAP<sup>5SA</sup> in HCT116 cells (<xref ref-type="fig" rid="fig6">Figure 6C</xref>). In contrast, knockdown of <italic>DDX6</italic> showed stimulative effect on the migration of both control and YAP<sup>5SA</sup>-expressing HCT116 cells, possibly due to the diverse functions of DDX6 (<xref ref-type="fig" rid="fig6s4">Figure 6—figure supplement 4A</xref>; <xref ref-type="bibr" rid="bib16">Di Stefano et al., 2019</xref>). To further demonstrate the potential role of P-body mediating the function of YAP/TAZ in CRC, we established YAP<sup>5SA</sup>-expressing HCT116 cell lines with stable knockdown of <italic>AJUBA</italic> and <italic>SAMD4A</italic> (<xref ref-type="fig" rid="fig6s4">Figure 6—figure supplement 4B and C</xref>). Indeed, both knockdown of <italic>AJUBA</italic> and <italic>SAMD4A</italic> suppressed the proliferation and cell migration of YAP<sup>5SA</sup>-expressing and control ‘parental’ HCT116 cells (<xref ref-type="fig" rid="fig6s4">Figure 6—figure supplement 4D and E</xref>). Collectively, our data demonstrate that P-body formation is required for the oncogenic function of YAP in CRC.</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Knockdown of P-body-related core genes suppresses the oncogenic function of YAP in colorectal cancer (CRC).</title><p>(<bold>A</bold>) CCK8 proliferation assays of control HCT116 cells with or without knockdown of <italic>DCP1A, LSM14A</italic> or <italic>DDX6</italic> and HCT116 cells stably expressing YAP<sup>5SA</sup> with or without knockdown of <italic>DCP1A, LSM14A,</italic> or <italic>DDX6</italic>. n = 5 biologically independent samples per group. (<bold>B, C</bold>) Colony formation assay (<bold>B</bold>) and Transwell assay (<bold>C</bold>) of control HCT116 cells with or without knockdown of <italic>DCP1A, LSM14A,</italic> or <italic>DDX6</italic> and HCT116 cells stably expressing YAP<sup>5SA</sup> with or without knockdown of <italic>DCP1A, LSM14A,</italic> or <italic>DDX6</italic>. n = 3 biologically independent samples per group. Two-way ANOVA (<bold>A</bold>) and one-way ANOVA (<bold>B, C</bold>) were performed to assess statistical significance in this figure. These data (<bold>A–C</bold>) are representative of three independent experiments.</p><p><supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>Original data for the statistical analysis in <xref ref-type="fig" rid="fig6">Figure 6A–C</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-88573-fig6-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-88573-fig6-v1.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>Knockdown efficiency and P-body reduction in <italic>DCP1A/LSM14A/DDX6</italic> knockdown HCT116 cells.</title><p>(<bold>A</bold>) qPCR and western blot analysis of the knockdown efficiency of <italic>DCP1A, LSM14A,</italic> and <italic>DDX6</italic> in HCT116 cells stably expressing YAP<sup>5SA</sup> with or without knockdown of <italic>DCP1A, LSM14A,</italic> or <italic>DDX6</italic>. n = 3 biologically independent samples per group. (<bold>B</bold>) Immunofluorescence analysis of DDX6 and DCP1A in HCT116 cells stably expressing YAP<sup>5SA</sup> with or without knockdown of <italic>DCP1A, LSM14A,</italic> or <italic>DDX6</italic>. Foci were counted in 100 cells per group. One-way ANOVA (<bold>A</bold>) and Kruskal–Wallis test (<bold>B</bold>) were performed to assess statistical significance.</p><p><supplementary-material id="fig6s1sdata1"><label>Figure 6—figure supplement 1—source data 1.</label><caption><title>Original data for the statistical analysis in <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A and B</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-88573-fig6-figsupp1-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig6s1sdata2"><label>Figure 6—figure supplement 1—source data 2.</label><caption><title>Original file for the western blot analysis in <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A</xref>.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-88573-fig6-figsupp1-data2-v1.pdf"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-88573-fig6-figsupp1-v1.tif"/></fig><fig id="fig6s2" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 2.</label><caption><title>Confirmation of <italic>DCP1A/ LSM14A/DDX6</italic> knockdown in YAP<sup>5SA</sup>-expressing HCT116 cells.</title><p>(<bold>A–C</bold>) qPCR and western blot analysis of the knockdown efficiency of <italic>DCP1A</italic> (<bold>A</bold>), <italic>DDX6</italic> (<bold>B</bold>), and <italic>LSM14A</italic> (<bold>C</bold>) in control HCT116 cells with or without knockdown of <italic>DCP1A</italic>, <italic>LSM14A,</italic> or <italic>DDX6</italic> and stable YAP<sup>5SA</sup> overexpression HCT116 cells with or without knockdown of <italic>DCP1A</italic>, <italic>LSM14A,</italic> or <italic>DDX6</italic>. n = 3 biologically independent samples per group. One-way ANOVA was performed to assess statistical significance.</p><p><supplementary-material id="fig6s2sdata1"><label>Figure 6—figure supplement 2—source data 1.</label><caption><title>Original data for the statistical analysis in <xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2A–C</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-88573-fig6-figsupp2-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig6s2sdata2"><label>Figure 6—figure supplement 2—source data 2.</label><caption><title>Original file for the western blot analysis in <xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2A–C</xref>.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-88573-fig6-figsupp2-data2-v1.pdf"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-88573-fig6-figsupp2-v1.tif"/></fig><fig id="fig6s3" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 3.</label><caption><title>Knockdown of <italic>DCP1A, LSM14A</italic> and <italic>DDX6</italic> downregulates cell mitosis and increases cell apoptosis in YAP<sup>5SA</sup>-expressing HCT116 cells.</title><p>(<bold>A, B</bold>) Cell apoptosis (<bold>A</bold>) and cell cycle (<bold>B</bold>) analysis of the control HCT116 cells with or without knockdown of <italic>DCP1A</italic>, <italic>LSM14A,</italic> or <italic>DDX6</italic> and stable YAP<sup>5SA</sup> overexpression HCT116 cells with or without knockdown of <italic>DCP1A, LSM14A,</italic> o<italic>r DDX6</italic>.</p><p><supplementary-material id="fig6s3sdata1"><label>Figure 6—figure supplement 3—source data 1.</label><caption><title>Original data for the bar plot in <xref ref-type="fig" rid="fig6s3">Figure 6—figure supplement 3A and B</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-88573-fig6-figsupp3-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-88573-fig6-figsupp3-v1.tif"/></fig><fig id="fig6s4" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 4.</label><caption><title>Knockdown of <italic>AJUBA</italic> or <italic>SAMD4A</italic> attenuates the oncogenic function of YAP in HCT116 cells.</title><p>(<bold>A</bold>) Transwell assay of control HCT116 cells with or without knockdown of <italic>DDX6</italic> and HCT116 cells stably expressing YAP<sup>5SA</sup> with or without knockdown of <italic>DDX6</italic>. n = 3 biologically independent samples per group. (<bold>B, C</bold>) qPCR (<bold>B</bold>) and western blot (<bold>C</bold>) analysis of the knockdown efficiency of <italic>AJUBA</italic> and <italic>SAMD4A</italic> in control HCT116 cells with or without knockdown of <italic>AJUBA</italic> or <italic>SAMD4A</italic> and stable YAP<sup>5SA</sup> overexpression HCT116 cells with or without knockdown of <italic>AJUBA</italic> or <italic>SAMD4A</italic>. n = 3 biologically independent samples per group. (<bold>D, E</bold>) CCK8 proliferation (n = 5) (<bold>D</bold>) and Transwell (<bold>E</bold>) assays of control HCT116 cells with or without knockdown of <italic>AJUBA</italic> or <italic>SAMD4A</italic> and stable YAP<sup>5SA</sup> overexpression HCT116 cells with or without knockdown of <italic>AJUBA</italic> or <italic>SAMD4A</italic>. One-way ANOVA (<bold>A, B, E</bold>) and two-way ANOVA (<bold>D</bold>) were performed to assess statistical significance in this figure. These data (<bold>A, D, E</bold>) are representative of three independent experiments.</p><p><supplementary-material id="fig6s4sdata1"><label>Figure 6—figure supplement 4—source data 1.</label><caption><title>Original data for the statistical analysis in <xref ref-type="fig" rid="fig6s4">Figure 6—figure supplement 4A–D</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-88573-fig6-figsupp4-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig6s4sdata2"><label>Figure 6—figure supplement 4—source data 2.</label><caption><title>Original file for the western blot analysis in <xref ref-type="fig" rid="fig6s4">Figure 6—figure supplement 4C</xref>.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-88573-fig6-figsupp4-data2-v1.pdf"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-88573-fig6-figsupp4-v1.tif"/></fig></fig-group></sec><sec id="s2-7"><title>Codependency of YAP/TEAD and essential P-body-related genes in pancancer CRISPR screens</title><p>Based on the observation that P-body disassembly attenuates YAP-driven cell proliferation in CRC cells, we speculated that cancer cells whose proliferation is dependent on YAP should also be vulnerable to knockout of essential P-body genes. To this end, we analyzed the Cancer Dependency Map (DepMap), which aims to systematically assess the effect of single-gene inactivation on cell proliferation by CRISPR and shRNA screens and define genetic dependencies in hundreds of cancer cell lines by integrating data pertaining to multiple molecular characteristics, such as <ext-link ext-link-type="uri" xlink:href="https://depmap.org/portal/ccle">Cancer Cell Line Encyclopedia</ext-link> (CCLE) data (<xref ref-type="bibr" rid="bib15">Dempster et al., 2021</xref>; <xref ref-type="bibr" rid="bib62">Tsherniak et al., 2017</xref>). As expected, by analyzing gene expression data from the CCLE, we observed a strong positive correlation between YAP-regulated P-body-related genes (<italic>SAMD4A, AJUBA,</italic> and <italic>WTIP</italic>) and canonical target genes of YAP (<italic>CTGF, CYR61, AXL</italic>, and <italic>AMOTL2</italic>) in cell lines across cancers or in cell lines of colorectal, breast and lung lineages (<xref ref-type="fig" rid="fig7">Figure 7A</xref>, <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1A and B</xref>). IHC analysis of 294 CRC tissues further showed the positive correlation between the expression of AJUBA/SAMD4A and YAP (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1D</xref>). Although there were no correlations between PNRC1 and YAP target genes in cell lines across cancers, we found that the mRNA level of <italic>PNRC1</italic> was negatively correlated with that of YAP target genes in cancer cells of thyroid and central nervous system (CNS) lineages (<xref ref-type="fig" rid="fig7">Figure 7B</xref>, <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1C</xref>). Next, we analyzed the effect of P-body core gene knockout in 1070 cancer cell lines (DepMap 22Q1 Public+Score, Chronos). Strikingly, knockout of the P-body-nucleation-determining genes <italic>DDX6</italic> and <italic>LSM14A</italic> inhibited proliferation in multiple cancer cell lines (negative Chronos score) (<xref ref-type="fig" rid="fig7">Figure 7C</xref>). Similar results were observed for <italic>EDC4</italic>, which is required for P-body aggregation (<xref ref-type="fig" rid="fig7">Figure 7C</xref>). Logically, correlations between dependency profiles suggest functionality in the same pathway or regulatory axis; thus, <italic>EDC4</italic> is strongly associated with multiple known P-body genes (<italic>DDX6, DCP2, EIF4ENIF1</italic>, etc.) (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>). Furthermore, we found that <italic>YAP</italic> ranked 14th among genes correlating with <italic>EDC4</italic> (<xref ref-type="fig" rid="fig7">Figure 7C</xref>, <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>). In addition, the YAP dependency score was positively correlated with the DDX6 and LSM14A scores (<xref ref-type="fig" rid="fig7">Figure 7C</xref>). Similar relationships were observed between EDC4/DDX6/LSM14A and TEAD1/3 (<xref ref-type="fig" rid="fig7s2">Figure 7—figure supplement 2</xref>). Last, we examined whether cell proliferation and cell migration are affected by the knockdown of <italic>DCP1A</italic> or <italic>LSM14A</italic> and overexpression of PNRC1 in MCF7, MDA-MB-231, and A549 cell lines, whose proliferation is dependent on YAP/TAZ activity. Consistent with the observation in HCT116 cells, the knockdown of <italic>DCP1A/LSM14A</italic> and overexpression of PNRC1 attenuated both cell proliferation and cell migration in these three YAP-dependent cancer cells (<xref ref-type="fig" rid="fig7s3">Figure 7—figure supplements 3</xref>–<xref ref-type="fig" rid="fig7s5">5</xref>). Collectively, the co-dependencies of YAP/TEAD and essential P-body genes further suggest that enhanced P-body formation plays a vital role in YAP-induced tumorigenesis.</p><fig-group><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>DepMap analysis reveals the co-dependencies of YAP/TEAD and P-body core genes in pancancer CRISPR screens.</title><p>(<bold>A</bold>) Positive correlations between the mRNA levels of <italic>CTGF</italic> and <italic>SAMD4A/AJUBA/WTIP</italic> in 1393 cancer cell lines. (<bold>B</bold>) Negative correlation between the mRNA levels of <italic>CTGF</italic> and <italic>PNRC1</italic> in brain cancer cell lines (n = 83) and thyroid cancer cell lines (n = 17). (<bold>C</bold>) Positive correlations between the dependency scores of <italic>YAP</italic> and <italic>DDX6/LSM14A/EDC4</italic> in 1070 cancer cell lines. The Chronos dependency scores were extracted from the DepMap database. The negative Chronos score indicates decreased cell proliferation upon gene knockout. Pearson correlation analysis was used to assess statistical significance. (<bold>D</bold>) In response to serum stimulation or under loss of contact inhibition or reduced ECM stiffness, activation of YAP enhances the P-body formation to promote colorectal cancer (CRC) cell proliferation and migration. Disruption of P-bodies by overexpression of the tumor suppressor gene PNRC1 or knockdown of P-body core genes could attenuate the cell proliferation and migration induced by activation of YAP in CRC cells.</p><p><supplementary-material id="fig7sdata1"><label>Figure 7—source data 1.</label><caption><title>Original data for the statistical analysis in <xref ref-type="fig" rid="fig7">Figure 7A–C</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-88573-fig7-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-88573-fig7-v1.tif"/></fig><fig id="fig7s1" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 1.</label><caption><title>Correlation analysis of the expression of YAP canonical target genes and YAP-related P-body genes.</title><p>(<bold>A</bold>) Positive correlations between the mRNA levels of YAP target genes (<italic>CYR61, AXL</italic>, and <italic>AMOTL2</italic>) and <italic>SAMD4A/AJUBA/WTIP</italic> in 1393 cancer cell lines. (<bold>B</bold>) Positive correlations between the mRNA levels of YAP target genes (<italic>CTGF</italic>) and <italic>SAMD4A/AJUBA/WTIP</italic> in brain cancer (n = 83), lung cancer (n = 207), and colorectal cancer (n = 71) cell lines. (<bold>C</bold>) Negative correlations between the mRNA levels of YAP target genes (<italic>CYR61, AXL,</italic> and <italic>AMOTL2</italic>) and <italic>PNRC1</italic> in brain cancer cell lines (n = 83) and thyroid cancer cell lines (n = 17). (<bold>D</bold>) IHC analysis of AJUBA, SAMD4A, and YAP protein expression in colorectal cancer tissues (n = 294). Pearson (<bold>A–C</bold>) and Spearman (<bold>D</bold>) correlation analysis was used to assess statistical significance.</p><p><supplementary-material id="fig7s1sdata1"><label>Figure 7—figure supplement 1—source data 1.</label><caption><title>Original data for the statistical analysis in <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1A–D</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-88573-fig7-figsupp1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-88573-fig7-figsupp1-v1.tif"/></fig><fig id="fig7s2" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 2.</label><caption><title>The <italic>TEAD1/3</italic> dependency scores are positively correlated with the <italic>EDC4/DDX6/LSM14A</italic> scores.</title><p>Positive correlations between the dependency scores of TEAD1/3 and DDX6/LSM14A/EDC4 in 1070 cancer cell lines. The Chronos dependency scores were extracted from the DepMap database. The negative Chronos score indicates decreased cell proliferation upon gene knockout. Pearson correlation analysis was used to assess statistical significance.</p><p><supplementary-material id="fig7s2sdata1"><label>Figure 7—figure supplement 2—source data 1.</label><caption><title>Original data for the statistical analysis in <xref ref-type="fig" rid="fig7s2">Figure 7—figure supplement 2A</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-88573-fig7-figsupp2-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-88573-fig7-figsupp2-v1.tif"/></fig><fig id="fig7s3" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 3.</label><caption><title>Knockdown of <italic>DCP1A/LSM14A</italic> and overexpression of PNRC1 suppress both cell proliferation and cell migration in A549 lung cancer cells.</title><p>(<bold>A</bold>) qPCR and western blot analysis of the knockdown efficiency of <italic>DCP1A / LSM14A</italic> or PNRC1 overexpression in A549 cells stably expressing PNRC1<sup>WT</sup>/PNRC1<sup>W300A</sup> or with knockdown of <italic>DCP1A</italic> and <italic>LSM14A</italic>. (<bold>B, C</bold>) CCK8 proliferation (n = 5 for PNRC1 OE, n = 3 for knockdown of <italic>DCP1A</italic> and <italic>LSM14A</italic>) (<bold>B</bold>) and Transwell (<bold>C</bold>) assays of A549 cells stably expressing PNRC1<sup>WT</sup>/PNRC1<sup>W300A</sup> or with knockdown of <italic>DCP1A</italic> and <italic>LSM14A</italic>. Two-way ANOVA (<bold>B</bold>) and one-way ANOVA (<bold>C</bold>) were performed to assess statistical significance in this figure. These data (<bold>B, C</bold>) are representative of two independent experiment.</p><p><supplementary-material id="fig7s3sdata1"><label>Figure 7—figure supplement 3—source data 1.</label><caption><title>Original data for the statistical analysis in <xref ref-type="fig" rid="fig7s3">Figure 7—figure supplement 3A–C</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-88573-fig7-figsupp3-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig7s3sdata2"><label>Figure 7—figure supplement 3—source data 2.</label><caption><title>Original file for the western blot analysis in <xref ref-type="fig" rid="fig7s3">Figure 7—figure supplement 3A</xref>.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-88573-fig7-figsupp3-data2-v1.pdf"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-88573-fig7-figsupp3-v1.tif"/></fig><fig id="fig7s4" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 4.</label><caption><title>Knockdown of <italic>DCP1A/LSM14A</italic> and overexpression of PNRC1 suppress both cell proliferation and cell migration in MCF7 breast cancer cells.</title><p>(<bold>A</bold>) qPCR and western blot analysis of the knockdown efficiency of DCP1A / LSM14A or PNRC1 overexpression in MCF7 cells stably expressing PNRC1WT/PNRC1W300A or with knockdown of DCP1A and LSM14A. (<bold>B, C</bold>) CCK8 proliferation (n = 6 for PNRC1 OE, n = 3 for knockdown of DCP1A and LSM14A) (<bold>B</bold>) and transwell (<bold>C</bold>) assays of MCF7 cells stably expressing PNRC1WT/PNRC1W300A or with knockdown of DCP1A and LSM14A. Two-way ANOVA (<bold>B</bold>) and one-way ANOVA (<bold>C</bold>) were performed to assess statistical significance in this figure. These data (<bold>B, C</bold>) are representative of 2 independent experiments.</p><p><supplementary-material id="fig7s4sdata1"><label>Figure 7—figure supplement 4—source data 1.</label><caption><title>Original data for the statistical analysis in <xref ref-type="fig" rid="fig7s4">Figure 7—figure supplement 4A–C</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-88573-fig7-figsupp4-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig7s4sdata2"><label>Figure 7—figure supplement 4—source data 2.</label><caption><title>Original file for the western blot analysis in <xref ref-type="fig" rid="fig7s4">Figure 7—figure supplement 4A</xref>.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-88573-fig7-figsupp4-data2-v1.pdf"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-88573-fig7-figsupp4-v1.tif"/></fig><fig id="fig7s5" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 5.</label><caption><title>Knockdown of <italic>DCP1A/LSM14A</italic> and overexpression of PNRC1 suppress both cell proliferation and cell migration in MDA-MB-231 breast cancer cells.</title><p>(<bold>A</bold>) qPCR and western blot analysis of the knockdown efficiency of DCP1A / LSM14A or PNRC1 overexpression in MDA-MB-231 cells stably expressing PNRC1WT/PNRC1W300A or with knockdown of DCP1A and LSM14A. (<bold>B, C</bold>) CCK8 proliferation (n = 6 for PNRC1 OE, n = 3 for knockdown of DCP1A and LSM14A) (<bold>B</bold>) and transwell (<bold>C</bold>) assays of MDA-MB-231 cells stably expressing PNRC1WT/PNRC1W300A or with knockdown of DCP1A and LSM14A. Two-way ANOVA (<bold>B</bold>) and one-way ANOVA (<bold>C</bold>) were performed to assess statistical significance in this figure. These data (<bold>B, C</bold>) are representative of 2 independent experiments.</p><p><supplementary-material id="fig7s5sdata1"><label>Figure 7—figure supplement 5—source data 1.</label><caption><title>Original data for the statistical analysis in <xref ref-type="fig" rid="fig7s5">Figure 7—figure supplement 5A–C</xref>.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-88573-fig7-figsupp5-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig7s5sdata2"><label>Figure 7—figure supplement 5—source data 2.</label><caption><title>Original file for the western blot analysis in <xref ref-type="fig" rid="fig7s5">Figure 7—figure supplement 5A</xref>.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-88573-fig7-figsupp5-data2-v1.pdf"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-88573-fig7-figsupp5-v1.tif"/></fig></fig-group></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Dysregulation of the Hippo pathway occurs in a variety of cancers, leading to cell transformation and diverse changes in tumor cells through activation of the YAP/TEAD transcriptional program (<xref ref-type="bibr" rid="bib7">Calses et al., 2019</xref>; <xref ref-type="bibr" rid="bib35">Kulkarni et al., 2020</xref>; <xref ref-type="bibr" rid="bib46">Nguyen and Yi, 2019</xref>; <xref ref-type="bibr" rid="bib63">Wang et al., 2018</xref>; <xref ref-type="bibr" rid="bib73">Zanconato et al., 2016</xref>). Here, we demonstrated the crucial role of YAP/TEAD in regulating P-body formation in multiple cancer cell lines. Through transcriptional stimulation of positive regulators of P-body formation (AJUBA, WTIP, and SAMD4A) and suppression of negative regulators of P-body formation (PNRC1), YAP enhances P-body formation and increases the number of P-bodies in cancer cells, which suggests that YAP is a positive regulator of P-body formation (<xref ref-type="fig" rid="fig7">Figure 7D</xref>). Studies of P-bodies in yeast have shown that the size and number of P-bodies increase upon exogenous and endogenous stress (<xref ref-type="bibr" rid="bib38">Luo et al., 2018</xref>). In addition, our study revealed that the number of P-bodies decreases under serum starvation, contact inhibition, and decreased ECM rigidity, possibly due to inactivation of YAP/TEAD. In contrast, a recent study, which provided the first link between YAP and P-bodies, implicated YAP as a negative regulator of P-bodies in KHSV-infected HUVECs (<xref ref-type="bibr" rid="bib9">Castle et al., 2021</xref>). Elizabeth L. Castle et al. reported that virus-encoded Kaposin B (KapB) induces actin stress fiber formation and disassembly of P-bodies, which requires RhoA activity and the YAP transcriptional program (<xref ref-type="bibr" rid="bib9">Castle et al., 2021</xref>). YAP-enhanced autophagic flux was proposed to participate in KapB-induced P-body disassembly, consistent with the concept that SGs and P-bodies are cleared by autophagy (<xref ref-type="bibr" rid="bib6">Buchan et al., 2013</xref>; <xref ref-type="bibr" rid="bib9">Castle et al., 2021</xref>). However, an increasing number of studies have reported the contradictory role of YAP in autophagy regulation, which suggests that YAP-mediated autophagy regulation is cell type- and context-dependent (<xref ref-type="bibr" rid="bib29">Jin et al., 2021</xref>; <xref ref-type="bibr" rid="bib47">Pei et al., 2022</xref>; <xref ref-type="bibr" rid="bib60">Totaro et al., 2019</xref>; <xref ref-type="bibr" rid="bib64">Wang et al., 2020</xref>). Furthermore, though YAP is required for the cell proliferation in HUVEC, transformed cell lines often display elevated baseline YAP/TAZ activity compared to normal cells and possess many alterations in growth signaling pathways including autophagy signaling (<xref ref-type="bibr" rid="bib46">Nguyen and Yi, 2019</xref>; <xref ref-type="bibr" rid="bib56">Shen and Stanger, 2015</xref>; <xref ref-type="bibr" rid="bib73">Zanconato et al., 2016</xref>). Thus, the contradictory observations regarding the role of YAP in modulating P-body formation between Elizabeth L. Castle et al.’s study and our study could be due to the different cell contexts and different cell conditions (baseline vs. KHSV infection).</p><p>In addition to the transcriptional regulation, P-body dynamics can also be modulated by post-translational modifications (<xref ref-type="bibr" rid="bib38">Luo et al., 2018</xref>). P-body constituent proteins, such as DCP1A and DCP2, are phosphorylated, which affects the protein interaction between DCP1A and DCP2 and subsequent P-body assembly (<xref ref-type="bibr" rid="bib11">Chiang et al., 2013</xref>; <xref ref-type="bibr" rid="bib70">Yoon et al., 2010</xref>). Previous studies have shown that DCP1A is hyperphosphorylated during mitosis and P-body assembly is dynamically changed across the cell cycle (<xref ref-type="bibr" rid="bib1">Aizer et al., 2013</xref>; <xref ref-type="bibr" rid="bib68">Yang et al., 2004</xref>). Meanwhile, Hippo signaling is intrinsically regulated and YAP can also be directly phosphorylated by CDK1 during cell cycle progression (<xref ref-type="bibr" rid="bib34">Kim et al., 2019</xref>; <xref ref-type="bibr" rid="bib69">Yang et al., 2013</xref>). Besides, as a direct regulator of P-body formation, AJUBA is also phosphorylated by CDK1 and mitotic phosphorylation of AJUBA promotes cancer cell proliferation (<xref ref-type="bibr" rid="bib10">Chen et al., 2016</xref>). Thus, we speculated that mitotic phosphorylation of YAP and AJUBA might also play a potential role in modulating P-body dynamics during cell cycle.</p><p>Compared with the role of SGs, the role of P-bodies in tumorigenesis and tumor progression is not well studied and is considered to be cancer type- or context-dependent (<xref ref-type="bibr" rid="bib36">Lavalée et al., 2021</xref>). TGF-β induces P-body formation and EMT in mammary epithelial cells, while inhibition of P-body formation by knockdown of DDX6 reverses EMT and suppresses breast cancer metastasis, implying a prometastatic function of P-bodies during the progression of breast cancer (<xref ref-type="bibr" rid="bib24">Hardy et al., 2017</xref>). In prostate cancer cells, dephosphorylation of EDC3 promotes the localization of EDC3-containing P-bodies and increases the P-body number (<xref ref-type="bibr" rid="bib5">Bearss et al., 2021</xref>). The increase in EDC3-containing P-bodies leads to sequestration or decay of a subset of mRNAs related to cell attachment and cell growth, such as <italic>ITGB1, ITGA6,</italic> and <italic>KLF4</italic>, which ultimately inhibits cell proliferation and cell migration (<xref ref-type="bibr" rid="bib5">Bearss et al., 2021</xref>). Of note, EDC3 and LSM14A compete for binding to the P-body core protein DDX6, and P-body formation still occurs constitutively in <italic>EDC3</italic> KO prostate cancer cells (<xref ref-type="bibr" rid="bib5">Bearss et al., 2021</xref>). Therefore, it can be speculated that there might be different types of P-bodies that contain different RNAs and exert protumorigenic or tumor-suppressive functions in different cell contexts. In CRC, DCP1A expression is elevated, which is associated with advanced TNM stages, lymph node metastasis and poor prognosis, and overexpression of DCP1A enhances P-body formation (<xref ref-type="bibr" rid="bib65">Wu et al., 2018a</xref>; <xref ref-type="bibr" rid="bib66">Wu et al., 2018b</xref>). These studies imply the potential protumorigenic function of P-bodies in CRC. Furthermore, our study showed that disruption or attenuation of P-body formation by knockdown of YAP-regulated P-body-related genes or the P-body core genes (<italic>DDX6, DCP1A, LSM14A</italic>) suppressed YAP-induced oncogenic phenotypes in CRC cells, such as cell proliferation and cell migration, further indicating the protumorigenic function of P-bodies in CRC or at least in CRC with active YAP. Numerous studies have demonstrated the YAP/TAZ promotes cancer cell growth through direct transcriptional regulation of genes related to cell cycle and cell apoptosis (<xref ref-type="bibr" rid="bib25">He et al., 2020</xref>; <xref ref-type="bibr" rid="bib28">Jang et al., 2017</xref>). Since P-bodies control the storage of untranslated mRNAs, YAP/TAZ might modulate gene expression by indirectly promoting P-body formation and the storage of untranslated target mRNAs. Future work is needed to explore P-body-enriched RNAs in CRC cells, which will further uncover the underlying mechanism by which P-bodies mediate the oncogenic function of YAP.</p><p>Recently, a study exploring new TSGs based on hemizygous deletions in multiple cancers revealed that PNRC1 is a novel tumor suppressor gene (<xref ref-type="bibr" rid="bib20">Gaviraghi et al., 2018</xref>). PNRC1 translocates the cytoplasmic DCP1A/DCP2 decapping complex into the nucleolus, which subsequently impedes rRNA transcription and ribosome biogenesis (<xref ref-type="bibr" rid="bib20">Gaviraghi et al., 2018</xref>). This translocation of DCP1A/DCP2 also leads to disassembly of P-bodies; thus, PNRC1 could also inhibit tumor cell proliferation by disrupting P-body formation. Moreover, hemizygous deletion of the 6q15 locus, where <italic>PNRC1</italic> is located, occurs in multiple cancers, including prostate, pancreatic, breast, and liver cancers (<xref ref-type="bibr" rid="bib20">Gaviraghi et al., 2018</xref>). Our findings suggest that transcriptional downregulation of <italic>PNRC1</italic> by YAP activation could be a new mechanism of PNRC1 dysregulation during tumorigenesis. In addition, multiple oncogenes, such as MYC, RAS, and PI3K, can activate rRNA transcription and boost ribosome biogenesis to support cancer cell proliferation (<xref ref-type="bibr" rid="bib48">Pelletier et al., 2018</xref>). The presence of the YAP-PNRC1 regulatory axis implies a potential role of YAP in ribosome biogenesis, which warrants further investigation in follow-up studies.</p><p>It has been shown that PNRC1 inhibits RAS- and MYC-driven tumor cell proliferation (<xref ref-type="bibr" rid="bib20">Gaviraghi et al., 2018</xref>). In addition, YAP acts downstream of mutant KRAS, and activation of YAP was found to drive KRAS-independent tumor relapse in preclinical models of pancreatic cancer (<xref ref-type="bibr" rid="bib30">Kapoor et al., 2014</xref>; <xref ref-type="bibr" rid="bib55">Shao et al., 2014</xref>; <xref ref-type="bibr" rid="bib74">Zhang et al., 2014</xref>). Strikingly, reexpression of PNRC1 also dramatically diminished the cell proliferation induced by YAP overexpression in CRC cells in our study. These data indicate that <italic>PNRC1</italic> is a tumor suppressor gene with a strong antitumor effect on various oncogenes; thus, reexpression of PNRC1 could be a promising anticancer therapeutic strategy. In addition, as an alternative to targeting the YAP/TEAD complex, drugs that inhibit downstream effectors of YAP/TAZ have shown efficacy in the clinic (<xref ref-type="bibr" rid="bib21">Gay et al., 2017</xref>; <xref ref-type="bibr" rid="bib45">Neesse et al., 2013</xref>; <xref ref-type="bibr" rid="bib46">Nguyen and Yi, 2019</xref>). The identification of the P-body as a new downstream effector of YAP/TAZ suggests that disruption of P-bodies might be a potential therapeutic strategy for tumors with active YAP. Although each P-body core gene performs multiple biological functions, unbiased functional CRISPR screening across cancer cell lines (DepMap) revealed that loss of function of a series of P-body core genes significantly suppresses proliferation in various tumor cell lines. The functional overlap in P-body assembly and the positive correlation between the dependency profiles of these P-body core genes imply the important role of P-bodies in tumor cell proliferation and cell survival. Several compounds, including translation inhibitors, have been reported to inhibit P-body formation (<xref ref-type="bibr" rid="bib40">Martínez et al., 2013</xref>; <xref ref-type="bibr" rid="bib58">Stribinskis and Ramos, 2007</xref>). Notably, actin polymerization can activate YAP (<xref ref-type="bibr" rid="bib59">Sun and Irvine, 2016</xref>). Methyl-chivosazol, an actin polymerization inhibitor, was found to be a strong inhibitor of P-body formation by screening of a library of compounds derived from myxobacteria (<xref ref-type="bibr" rid="bib40">Martínez et al., 2013</xref>). However, these small molecules indirectly target P-bodies and show extensive effects on cells (<xref ref-type="bibr" rid="bib40">Martínez et al., 2013</xref>; <xref ref-type="bibr" rid="bib58">Stribinskis and Ramos, 2007</xref>). Thus, the development of inhibitors directly targeting P-body core proteins will provide a chemical tool for exploring the function of P-bodies in tumors and assess the therapeutic efficacy of P-body disassembly in cancer. Overall, our study reveals the P-body as a new downstream effector of YAP/TAZ, which opens a new possibility of targeting P-body assembly to combat tumors (<xref ref-type="fig" rid="fig7">Figure 7D</xref>).</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Cell culture and transfection</title><p>HEK293T, NIH3T3, HCT116, MCF7, MDA-MB-231, and A549 cells were purchased from the American Type Culture Collection (ATCC) and authenticated by short tandem repeat analysis. HEK293T, NIH3T3, HCT116, and MDA-MB-231 cells were cultured in Dulbecco's Modified Eagle Medium (DMEM)/high-glucose (HyClone) supplemented with 10% fetal bovine serum (FBS), 100 units/ml penicillin, and 100 μg/ml streptomycin (Sangon Biotech) at 37°C in 5% CO<sub>2</sub>. MCF7 cells were cultured in Minimum Essential Medium (MEM)/high-glucose (HyClone), A549 cells were cultured in RPMI-1640 high-glucose medium (HyClone), and the other culture conditions were the same as those used for HCT116 cells. Corning TC-treated Culture Dish was used for routine cell culture. For the cell culture with 2D polyacrylamide-based hydrogels, hydrogels of high (40.40 ± 2.39 kPa) or low (1.00 ± 0.31 kPa) stiffness were generated according to the published protocol (<xref ref-type="bibr" rid="bib61">Tse and Engler, 2010</xref>). Fibronectin solution (3 μg/ml) and Sigmacote were used to coat the surface of the hydrogels. PEI (Polysciences) and Lipofectamine 2000 (Invitrogen) were used for plasmid transfection. Lipofectamine RNAiMAX (Invitrogen) was used for siRNA transfection.</p></sec><sec id="s4-2"><title>Plasmids and reagents</title><p>Full-length <italic>PNRC1</italic> cDNA was inserted into the pQCXIH vector, and the mutant pQCXIH-FLAG-<italic>PNRC1<sup>W300A</sup></italic> plasmid was constructed by using a KOD mutagenesis kit (Toyobo, Osaka, Japan) according to the manufacturer’s instructions. The pBABE-FLAG-<italic>YAP<sup>5SA</sup>/YAP<sup>5SA-S94A</sup></italic> and pRK7-FLAG-<italic>YAP<sup>5SA</sup>/YAP<sup>5SA-S94A</sup></italic> plasmids were obtained from laboratory storage. To generate the shRNA constructs targeting human <italic>TAZ</italic>, the targeting sequences were inserted into the pLKO.1-puro vector. The shRNA constructs targeting human <italic>YAP, SAMD4A, AJUBA, DDX6, DCP1A,</italic> and <italic>LSM14A</italic> were generated by using the pLKO.1-hygro vector. The <italic>PNRC1</italic> promoter and intron reporter plasmids and TEAD binding site mutant reporter plasmids were constructed by using the pGL3-Basic vector. siRNA/shRNA was used for all RNA silencing experiments in the study. The siRNA oligos targeting <italic>CHD4, RBBP4, PNRC1, SAMD4A, AJUBA, YAP,</italic> and <italic>TAZ</italic> were synthesized by Shanghai Genepharma Co., Ltd. The shRNA and siRNA targeting sequences and the primers used for plasmid construction are listed in <xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>. The following antibodies were used in this study: anti-FLAG (D6W5B, CST), anti-FLAG (M2, Sigma), anti-YAP/TAZ (D24E4, CST), anti-YAP (sc-101199, Santa Cruz), anti-TEAD4 (ab58310, Abcam), anti-CHD4 (14173-1-AP, Proteintech), anti-DDX6 (A9634, ABclonal), anti-DCP1A (A6824, ABclonal), anti-LSM14A (18336-1-AP, Proteintech), anti-AJUBA (A22039, ABclonal), anti-SAMD4A (17387-1-AP, Proteintech), and anti-PNRC1 (51052-1-AP, Proteintech).</p></sec><sec id="s4-3"><title>Cell proliferation, colony formation, and cell migration assays</title><p>For the proliferation assay, cells (1 × 10<sup>3</sup> per well) were seeded into a 96-well plate and cultured for 5 d. Cell viability was measured every day with a Cell Counting Kit 8 (CCK8) (Vazyme) according to the manufacturer’s instructions. Briefly, 10 μl of CCK8 reagent was added to each well and incubated for 2 hr. The absorbance at 450 nm was measured with a microplate reader to determine the relative numbers of viable cells. For the colony formation assay, cells (1 × 10<sup>3</sup> per well) were seeded and cultured in six-well plates for 2 wk. Then, the cells were stained with 1% crystal violet, and the number of colonies in each well was counted. For the cell migration assay, cells (1.5 × 10<sup>5</sup> per well) in DMEM/high-glucose containing 0.1% FBS were seeded in the upper compartment of a Transwell chamber, while DMEM/high-glucose containing 10% FBS was placed in the lower compartment. After 60 hr, migrated cells were stained with 1% crystal violet and counted.</p></sec><sec id="s4-4"><title>Cell cycle and cell apoptosis assays</title><p>Cell cycle and cell apoptosis assays were performed according to the manufacturer’s instruction (FITC Annexin V Apoptosis Detection Kit I, BD, 556547; PI/RNase staining buffer, BD, 550825).</p></sec><sec id="s4-5"><title>qPCR, ChIP, and luciferase reporter assays</title><p>qPCR and ChIP were performed as previously described (<xref ref-type="bibr" rid="bib77">Zhu et al., 2020</xref>). For the luciferase assay, HEK293T cells were seeded in 24-well plates, incubated overnight to 50% confluence, and then co-transfected with the <italic>PNRC1</italic> luciferase reporter plasmid and the FLAG-<italic>YAP<sup>5SA</sup></italic> or FLAG-<italic>YAP<sup>5SA-S94A</sup></italic> plasmid. A Renilla luciferase plasmid was used as the control. After 24–36 hr, luciferase activity was measured by using a dual-luciferase reporter assay (Promega) and normalized to Renilla luciferase activity. For the luciferase assay using the <italic>YAP/TAZ</italic> knockdown of HCT116 cells, stable HCT116 cells were seeded in 24-well plates and co-transfected with the <italic>PNRC1</italic> luciferase reporter and Renilla luciferase plasmids for 6 hr. Then, cells were replated to six-well plates and cultured for 24–36 hr at a low cell density before measuring the luciferase activity.</p></sec><sec id="s4-6"><title>Immunofluorescence staining</title><p>Cells were seeded in glass-bottom cell culture dishes one night before IF staining. The cells were washed with phosphate-buffered saline (PBS) and fixed with 4% paraformaldehyde. After the cells were permeabilized with 0.1% Triton X-100 at room temperature (RT) for 5 min, they were blocked with 3% Bovine Serum Albumin (BSA) at RT for 1 hr. Then, the cells were incubated overnight with a rabbit anti-DDX6/DCP1A/LSM14A antibody (1:250) or a mouse anti-FLAG (M2) antibody (1:150) or mouse anti-YAP antibody (1:100). After a 1 hr incubation with Cy3-conjugated mouse and Alexa Fluor 488-conjugated rabbit secondary antibodies followed by a 1 min incubation with 0.1 μg/ml DAPI, the cells were visualized with an Olympus IX81 microscope.</p></sec><sec id="s4-7"><title>Xenograft assay and immunohistochemistry</title><p>Nude mice (4–6 weeks old, male) were obtained from SLAC Laboratory Animals LLC, Shanghai, China. All mouse procedures were approved by the Xinhua Hospital Animal Care and Use Committee. Male nude mice (4–6 weeks old) were randomly divided into four groups (n = 6 mice per group) and injected in the right flank with 2 × 10<sup>6</sup> of the indicated stable HCT116 cells resuspended in 100 μl of PBS. Mice were sacrificed on day 21, and the xenograft tumors were removed, photographed, and paraffin embedded for sectioning. The xenograft tumors were sectioned for H&amp;E staining and immunohistochemical staining with anti-ki67 and anti-PNRC1 antibodies as described previously (<xref ref-type="bibr" rid="bib77">Zhu et al., 2020</xref>).</p></sec><sec id="s4-8"><title>Colorectal cancer specimen</title><p>Patients with CRC who underwent curative surgery without prior treatments at the Department of Colorectal and Anal Surgery, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, between January 2008 and December 2018 were enrolled. Institutional review board approval and informed consent were obtained for all sample collections. None of the patients had any history of other tumors. Tumors and paired paracancerous normal tissues were collected during surgery. The generation of the CRC tissue array has been described, and the IHC analysis of the CRC tissue array was performed according to our previous study (<xref ref-type="bibr" rid="bib77">Zhu et al., 2020</xref>).</p></sec><sec id="s4-9"><title>Statistical analysis</title><p>Statistical analysis was performed by using GraphPad Prism 8.0.2 and SPSS 22.0. Typically, differences between two groups were evaluated using two-tailed Student’s <italic>t</italic>-test or the chi-square test as indicated in the figure legends. One-way ANOVA was used for the experiments with more than two groups. Mann–Whitney <italic>U</italic> test and Kruskal–Wallis test were used for statistical analysis of the foci number in IF staining assay. Two-way ANOVA was used for statistical analysis of CCK8 assay. Paired Student’s <italic>t</italic>-test was performed to assess the statistical significance of differential <italic>PNRC1</italic> mRNA expression in 16 pairs of CRC and adjacent normal tissues. Pearson correlation analysis was used to statistically assess correlations of mRNA levels or co-dependencies from the DepMap database. The results are shown as averages; the error bars indicate the SDs. p-Values less than 0.05 were considered significant (*p&lt;0.05; **p&lt;0.01; ***p&lt;0.001; ****p&lt;0.0001).</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con2"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con3"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con4"><p>Software</p></fn><fn fn-type="con" id="con5"><p>Resources, Funding acquisition</p></fn><fn fn-type="con" id="con6"><p>Validation</p></fn><fn fn-type="con" id="con7"><p>Data curation, Supervision, Funding acquisition</p></fn><fn fn-type="con" id="con8"><p>Conceptualization, Supervision, Funding acquisition, Writing – original draft, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Patients with colorectal cancer who underwent curative surgery without prior treatments at the Department of Colorectal and Anal Surgery, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, between January 2008 and December 2018 were enrolled.</p></fn><fn fn-type="other"><p>All mouse studies were approved, and all animals were manipulated according to the protocols approved by the Animal Care and Use Committees of Xinhua Hospital and animal care was conducted in accordance with institutional guidelines. According to the criteria of the Animal Care and Use Committee of Xinhua Hospital, the maximal tumor burden permitted was &lt;10% body weight, at no point did any mice exceed maximal tumor burden. Mice were housed in pathogen-free and ventilated cages, and allowed free access to irradiated food and autoclaved water ad libitum in a 12 h light/dark cycle, with room temperature at 21 °C and humidity between 45 and 65%. Male BALB/c nude mice of ~4-6 weeks of age were purchased from GemPharmatech, Shanghai, China.</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>The expression of P-body genes in YAP/TAZ knockdown HCT116 cells.</title><p>The differentially expressed genes in YAP/TAZ knockdown HCT116 cells were analyzed by RNA-seq (GSE176475). The expression levels of genes that were annotated as related to P-bodies are included in this supplementary file.</p></caption><media xlink:href="elife-88573-supp1-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>Top 100 correlation for EDC4 in CRISPR (DepMap 22Q1 Public Score, Chronos).</title><p>The gene dependency scores of the top 100 genes that are correlated with EDC4 were downloaded from the Cancer Dependency Map (DepMap) database.</p></caption><media xlink:href="elife-88573-supp2-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp3"><label>Supplementary file 3.</label><caption><title>siRNA, shRNA, and primers used in this study.</title><p>The sequences of the siRNA, shRNA, and primers used in this study are included in this supplementary file.</p></caption><media xlink:href="elife-88573-supp3-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-88573-mdarchecklist1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>All WB source data generated during this study are included in the manuscript and supporting files. Source data files have been provided for figures.</p><p>The following previously published dataset was used:</p><p><element-citation publication-type="data" specific-use="references" id="dataset1"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>Y</given-names></name><name><surname>Zhu</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>Identification of differential expressed genes after HHEX/YAP/TAZ/TEAD knockdown in colorectal cancer cells</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE176475">GSE176475</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>This work was sponsored by the National Key R&amp;D Program of China (2019YFC1316002), the National Natural Science Foundation of China (82172916, 82372648, 82073056, 82273022), and the Program for Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning (to C-YL).</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aizer</surname><given-names>A</given-names></name><name><surname>Kafri</surname><given-names>P</given-names></name><name><surname>Kalo</surname><given-names>A</given-names></name><name><surname>Shav-Tal</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The P body protein Dcp1a is hyper-phosphorylated during mitosis</article-title><source>PLOS ONE</source><volume>8</volume><elocation-id>e49783</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0049783</pub-id><pub-id pub-id-type="pmid">23300942</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>P</given-names></name><name><surname>Kedersha</surname><given-names>N</given-names></name><name><surname>Ivanov</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Stress granules, P-bodies and cancer</article-title><source>Biochimica et Biophysica Acta</source><volume>1849</volume><fpage>861</fpage><lpage>870</lpage><pub-id pub-id-type="doi">10.1016/j.bbagrm.2014.11.009</pub-id><pub-id pub-id-type="pmid">25482014</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aragona</surname><given-names>M</given-names></name><name><surname>Panciera</surname><given-names>T</given-names></name><name><surname>Manfrin</surname><given-names>A</given-names></name><name><surname>Giulitti</surname><given-names>S</given-names></name><name><surname>Michielin</surname><given-names>F</given-names></name><name><surname>Elvassore</surname><given-names>N</given-names></name><name><surname>Dupont</surname><given-names>S</given-names></name><name><surname>Piccolo</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>A mechanical checkpoint controls multicellular growth through YAP/TAZ regulation by actin-processing factors</article-title><source>Cell</source><volume>154</volume><fpage>1047</fpage><lpage>1059</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2013.07.042</pub-id><pub-id pub-id-type="pmid">23954413</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baez</surname><given-names>MV</given-names></name><name><surname>Boccaccio</surname><given-names>GL</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Mammalian Smaug is a translational repressor that forms cytoplasmic foci similar to stress granules</article-title><source>The Journal of Biological Chemistry</source><volume>280</volume><fpage>43131</fpage><lpage>43140</lpage><pub-id pub-id-type="doi">10.1074/jbc.M508374200</pub-id><pub-id pub-id-type="pmid">16221671</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bearss</surname><given-names>JJ</given-names></name><name><surname>Padi</surname><given-names>SK</given-names></name><name><surname>Singh</surname><given-names>N</given-names></name><name><surname>Cardo‐Vila</surname><given-names>M</given-names></name><name><surname>Song</surname><given-names>JH</given-names></name><name><surname>Mouneimne</surname><given-names>G</given-names></name><name><surname>Fernandes</surname><given-names>N</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Harter</surname><given-names>MR</given-names></name><name><surname>Gard</surname><given-names>JM</given-names></name><name><surname>Cress</surname><given-names>AE</given-names></name><name><surname>Peti</surname><given-names>W</given-names></name><name><surname>Nelson</surname><given-names>AD</given-names></name><name><surname>Buchan</surname><given-names>JR</given-names></name><name><surname>Kraft</surname><given-names>AS</given-names></name><name><surname>Okumura</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>EDC3 phosphorylation regulates growth and invasion through controlling P‐body formation and dynamics</article-title><source>EMBO Reports</source><volume>22</volume><elocation-id>e50835</elocation-id><pub-id pub-id-type="doi">10.15252/embr.202050835</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buchan</surname><given-names>JR</given-names></name><name><surname>Kolaitis</surname><given-names>R-M</given-names></name><name><surname>Taylor</surname><given-names>JP</given-names></name><name><surname>Parker</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Eukaryotic stress granules are cleared by autophagy and Cdc48/VCP Function</article-title><source>Cell</source><volume>153</volume><fpage>1461</fpage><lpage>1474</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2013.05.037</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calses</surname><given-names>PC</given-names></name><name><surname>Crawford</surname><given-names>JJ</given-names></name><name><surname>Lill</surname><given-names>JR</given-names></name><name><surname>Dey</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Hippo pathway in cancer: aberrant regulation and therapeutic opportunities</article-title><source>Trends in Cancer</source><volume>5</volume><fpage>297</fpage><lpage>307</lpage><pub-id pub-id-type="doi">10.1016/j.trecan.2019.04.001</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calvo</surname><given-names>F</given-names></name><name><surname>Ege</surname><given-names>N</given-names></name><name><surname>Grande-Garcia</surname><given-names>A</given-names></name><name><surname>Hooper</surname><given-names>S</given-names></name><name><surname>Jenkins</surname><given-names>RP</given-names></name><name><surname>Chaudhry</surname><given-names>SI</given-names></name><name><surname>Harrington</surname><given-names>K</given-names></name><name><surname>Williamson</surname><given-names>P</given-names></name><name><surname>Moeendarbary</surname><given-names>E</given-names></name><name><surname>Charras</surname><given-names>G</given-names></name><name><surname>Sahai</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Mechanotransduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts</article-title><source>Nature Cell Biology</source><volume>15</volume><fpage>637</fpage><lpage>646</lpage><pub-id pub-id-type="doi">10.1038/ncb2756</pub-id><pub-id pub-id-type="pmid">23708000</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castle</surname><given-names>EL</given-names></name><name><surname>Robinson</surname><given-names>CA</given-names></name><name><surname>Douglas</surname><given-names>P</given-names></name><name><surname>Rinker</surname><given-names>KD</given-names></name><name><surname>Corcoran</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Viral manipulation of a mechanoresponsive signaling axis disassembles processing bodies</article-title><source>Molecular and Cellular Biology</source><volume>41</volume><elocation-id>e0039921</elocation-id><pub-id pub-id-type="doi">10.1128/MCB.00399-21</pub-id><pub-id pub-id-type="pmid">34516278</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Stauffer</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Dong</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Ajuba phosphorylation by CDK1 promotes cell proliferation and tumorigenesis</article-title><source>Journal of Biological Chemistry</source><volume>291</volume><fpage>14761</fpage><lpage>14772</lpage><pub-id pub-id-type="doi">10.1074/jbc.M116.722751</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiang</surname><given-names>PY</given-names></name><name><surname>Shen</surname><given-names>YF</given-names></name><name><surname>Su</surname><given-names>YL</given-names></name><name><surname>Kao</surname><given-names>CH</given-names></name><name><surname>Lin</surname><given-names>NY</given-names></name><name><surname>Hsu</surname><given-names>PH</given-names></name><name><surname>Tsai</surname><given-names>MD</given-names></name><name><surname>Wang</surname><given-names>SC</given-names></name><name><surname>Chang</surname><given-names>GD</given-names></name><name><surname>Lee</surname><given-names>SC</given-names></name><name><surname>Chang</surname><given-names>CJ</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Phosphorylation of mRNA decapping protein Dcp1a by the ERK signaling pathway during early differentiation of 3T3-L1 preadipocytes</article-title><source>PLOS ONE</source><volume>8</volume><elocation-id>e61697</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0061697</pub-id><pub-id pub-id-type="pmid">23637887</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Das Thakur</surname><given-names>M</given-names></name><name><surname>Feng</surname><given-names>Y</given-names></name><name><surname>Jagannathan</surname><given-names>R</given-names></name><name><surname>Seppa</surname><given-names>MJ</given-names></name><name><surname>Skeath</surname><given-names>JB</given-names></name><name><surname>Longmore</surname><given-names>GD</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Ajuba LIM proteins are negative regulators of the Hippo signaling pathway</article-title><source>Current Biology</source><volume>20</volume><fpage>657</fpage><lpage>662</lpage><pub-id pub-id-type="doi">10.1016/j.cub.2010.02.035</pub-id><pub-id pub-id-type="pmid">20303269</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dasgupta</surname><given-names>I</given-names></name><name><surname>McCollum</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Control of cellular responses to mechanical cues through YAP/TAZ regulation</article-title><source>The Journal of Biological Chemistry</source><volume>294</volume><fpage>17693</fpage><lpage>17706</lpage><pub-id pub-id-type="doi">10.1074/jbc.REV119.007963</pub-id><pub-id pub-id-type="pmid">31594864</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Decker</surname><given-names>CJ</given-names></name><name><surname>Parker</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>P-bodies and stress granules: possible roles in the control of translation and mRNA degradation</article-title><source>Cold Spring Harbor Perspectives in Biology</source><volume>4</volume><elocation-id>a012286</elocation-id><pub-id pub-id-type="doi">10.1101/cshperspect.a012286</pub-id><pub-id pub-id-type="pmid">22763747</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dempster</surname><given-names>JM</given-names></name><name><surname>Boyle</surname><given-names>I</given-names></name><name><surname>Vazquez</surname><given-names>F</given-names></name><name><surname>Root</surname><given-names>DE</given-names></name><name><surname>Boehm</surname><given-names>JS</given-names></name><name><surname>Hahn</surname><given-names>WC</given-names></name><name><surname>Tsherniak</surname><given-names>A</given-names></name><name><surname>McFarland</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Chronos: a cell population dynamics model of CRISPR experiments that improves inference of gene fitness effects</article-title><source>Genome Biology</source><volume>22</volume><elocation-id>343</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-021-02540-7</pub-id><pub-id pub-id-type="pmid">34930405</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Stefano</surname><given-names>B</given-names></name><name><surname>Luo</surname><given-names>E-C</given-names></name><name><surname>Haggerty</surname><given-names>C</given-names></name><name><surname>Aigner</surname><given-names>S</given-names></name><name><surname>Charlton</surname><given-names>J</given-names></name><name><surname>Brumbaugh</surname><given-names>J</given-names></name><name><surname>Ji</surname><given-names>F</given-names></name><name><surname>Rabano Jiménez</surname><given-names>I</given-names></name><name><surname>Clowers</surname><given-names>KJ</given-names></name><name><surname>Huebner</surname><given-names>AJ</given-names></name><name><surname>Clement</surname><given-names>K</given-names></name><name><surname>Lipchina</surname><given-names>I</given-names></name><name><surname>de Kort</surname><given-names>MAC</given-names></name><name><surname>Anselmo</surname><given-names>A</given-names></name><name><surname>Pulice</surname><given-names>J</given-names></name><name><surname>Gerli</surname><given-names>MFM</given-names></name><name><surname>Gu</surname><given-names>H</given-names></name><name><surname>Gygi</surname><given-names>SP</given-names></name><name><surname>Sadreyev</surname><given-names>RI</given-names></name><name><surname>Meissner</surname><given-names>A</given-names></name><name><surname>Yeo</surname><given-names>GW</given-names></name><name><surname>Hochedlinger</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The RNA Helicase DDX6 controls cellular plasticity by modulating P-body homeostasis</article-title><source>Cell Stem Cell</source><volume>25</volume><fpage>622</fpage><lpage>638</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2019.08.018</pub-id><pub-id pub-id-type="pmid">31588046</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Driskill</surname><given-names>JH</given-names></name><name><surname>Pan</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The hippo pathway in liver homeostasis and pathophysiology</article-title><source>Annual Review of Pathology</source><volume>16</volume><fpage>299</fpage><lpage>322</lpage><pub-id pub-id-type="doi">10.1146/annurev-pathol-030420-105050</pub-id><pub-id pub-id-type="pmid">33234023</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dupont</surname><given-names>S</given-names></name><name><surname>Morsut</surname><given-names>L</given-names></name><name><surname>Aragona</surname><given-names>M</given-names></name><name><surname>Enzo</surname><given-names>E</given-names></name><name><surname>Giulitti</surname><given-names>S</given-names></name><name><surname>Cordenonsi</surname><given-names>M</given-names></name><name><surname>Zanconato</surname><given-names>F</given-names></name><name><surname>Le Digabel</surname><given-names>J</given-names></name><name><surname>Forcato</surname><given-names>M</given-names></name><name><surname>Bicciato</surname><given-names>S</given-names></name><name><surname>Elvassore</surname><given-names>N</given-names></name><name><surname>Piccolo</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Role of YAP/TAZ in mechanotransduction</article-title><source>Nature</source><volume>474</volume><fpage>179</fpage><lpage>183</lpage><pub-id pub-id-type="doi">10.1038/nature10137</pub-id><pub-id pub-id-type="pmid">21654799</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>R</given-names></name><name><surname>Kim</surname><given-names>NG</given-names></name><name><surname>Gumbiner</surname><given-names>BM</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Regulation of Hippo pathway by mitogenic growth factors via phosphoinositide 3-kinase and phosphoinositide-dependent kinase-1</article-title><source>PNAS</source><volume>110</volume><fpage>2569</fpage><lpage>2574</lpage><pub-id pub-id-type="doi">10.1073/pnas.1216462110</pub-id><pub-id pub-id-type="pmid">23359693</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaviraghi</surname><given-names>M</given-names></name><name><surname>Vivori</surname><given-names>C</given-names></name><name><surname>Pareja Sanchez</surname><given-names>Y</given-names></name><name><surname>Invernizzi</surname><given-names>F</given-names></name><name><surname>Cattaneo</surname><given-names>A</given-names></name><name><surname>Santoliquido</surname><given-names>BM</given-names></name><name><surname>Frenquelli</surname><given-names>M</given-names></name><name><surname>Segalla</surname><given-names>S</given-names></name><name><surname>Bachi</surname><given-names>A</given-names></name><name><surname>Doglioni</surname><given-names>C</given-names></name><name><surname>Pelechano</surname><given-names>V</given-names></name><name><surname>Cittaro</surname><given-names>D</given-names></name><name><surname>Tonon</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Tumor suppressor PNRC1 blocks rRNA maturation by recruiting the decapping complex to the nucleolus</article-title><source>The EMBO Journal</source><volume>37</volume><elocation-id>e99179</elocation-id><pub-id pub-id-type="doi">10.15252/embj.201899179</pub-id><pub-id pub-id-type="pmid">30373810</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gay</surname><given-names>CM</given-names></name><name><surname>Balaji</surname><given-names>K</given-names></name><name><surname>Byers</surname><given-names>LA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Giving AXL the axe: targeting AXL in human malignancy</article-title><source>British Journal of Cancer</source><volume>116</volume><fpage>415</fpage><lpage>423</lpage><pub-id pub-id-type="doi">10.1038/bjc.2016.428</pub-id><pub-id pub-id-type="pmid">28072762</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>Y</given-names></name><name><surname>Zhu</surname><given-names>Z</given-names></name><name><surname>Huang</surname><given-names>Z</given-names></name><name><surname>Cui</surname><given-names>L</given-names></name><name><surname>Yu</surname><given-names>W</given-names></name><name><surname>Hong</surname><given-names>W</given-names></name><name><surname>Zhou</surname><given-names>Z</given-names></name><name><surname>Du</surname><given-names>P</given-names></name><name><surname>Liu</surname><given-names>CY</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>CK2-induced cooperation of HHEX with the YAP-TEAD4 complex promotes colorectal tumorigenesis</article-title><source>Nature Communications</source><volume>13</volume><elocation-id>4995</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-022-32674-6</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanahan</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Hallmarks of cancer: new dimensions</article-title><source>Cancer Discovery</source><volume>12</volume><fpage>31</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-21-1059</pub-id><pub-id pub-id-type="pmid">35022204</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hardy</surname><given-names>SD</given-names></name><name><surname>Shinde</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>WH</given-names></name><name><surname>Wendt</surname><given-names>MK</given-names></name><name><surname>Geahlen</surname><given-names>RL</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Regulation of epithelial-mesenchymal transition and metastasis by TGF-β, P-bodies, and autophagy</article-title><source>Oncotarget</source><volume>8</volume><fpage>103302</fpage><lpage>103314</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.21871</pub-id><pub-id pub-id-type="pmid">29262563</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>L</given-names></name><name><surname>Yuan</surname><given-names>L</given-names></name><name><surname>Yu</surname><given-names>W</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Jiang</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Feng</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Feng</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Zeng</surname><given-names>YA</given-names></name><name><surname>Hui</surname><given-names>L</given-names></name><name><surname>Wu</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A regulation loop between YAP and NR4A1 balances cell proliferation and apoptosis</article-title><source>Cell Reports</source><volume>33</volume><elocation-id>108284</elocation-id><pub-id pub-id-type="doi">10.1016/j.celrep.2020.108284</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hubstenberger</surname><given-names>A</given-names></name><name><surname>Courel</surname><given-names>M</given-names></name><name><surname>Bénard</surname><given-names>M</given-names></name><name><surname>Souquere</surname><given-names>S</given-names></name><name><surname>Ernoult-Lange</surname><given-names>M</given-names></name><name><surname>Chouaib</surname><given-names>R</given-names></name><name><surname>Yi</surname><given-names>Z</given-names></name><name><surname>Morlot</surname><given-names>JB</given-names></name><name><surname>Munier</surname><given-names>A</given-names></name><name><surname>Fradet</surname><given-names>M</given-names></name><name><surname>Daunesse</surname><given-names>M</given-names></name><name><surname>Bertrand</surname><given-names>E</given-names></name><name><surname>Pierron</surname><given-names>G</given-names></name><name><surname>Mozziconacci</surname><given-names>J</given-names></name><name><surname>Kress</surname><given-names>M</given-names></name><name><surname>Weil</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>P-Body purification reveals the condensation of repressed mRNA Regulons</article-title><source>Molecular Cell</source><volume>68</volume><fpage>144</fpage><lpage>157</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2017.09.003</pub-id><pub-id pub-id-type="pmid">28965817</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>James</surname><given-names>V</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Foxler</surname><given-names>DE</given-names></name><name><surname>de Moor</surname><given-names>CH</given-names></name><name><surname>Kong</surname><given-names>YW</given-names></name><name><surname>Webb</surname><given-names>TM</given-names></name><name><surname>Self</surname><given-names>TJ</given-names></name><name><surname>Feng</surname><given-names>Y</given-names></name><name><surname>Lagos</surname><given-names>D</given-names></name><name><surname>Chu</surname><given-names>C-Y</given-names></name><name><surname>Rana</surname><given-names>TM</given-names></name><name><surname>Morley</surname><given-names>SJ</given-names></name><name><surname>Longmore</surname><given-names>GD</given-names></name><name><surname>Bushell</surname><given-names>M</given-names></name><name><surname>Sharp</surname><given-names>TV</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>LIM-domain proteins, LIMD1, Ajuba, and WTIP are required for microRNA-mediated gene silencing</article-title><source>PNAS</source><volume>107</volume><fpage>12499</fpage><lpage>12504</lpage><pub-id pub-id-type="doi">10.1073/pnas.0914987107</pub-id><pub-id pub-id-type="pmid">20616046</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jang</surname><given-names>W</given-names></name><name><surname>Kim</surname><given-names>T</given-names></name><name><surname>Koo</surname><given-names>JS</given-names></name><name><surname>Kim</surname><given-names>SK</given-names></name><name><surname>Lim</surname><given-names>DS</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Mechanical cue-induced YAP instructs Skp2-dependent cell cycle exit and oncogenic signaling</article-title><source>The EMBO Journal</source><volume>36</volume><fpage>2510</fpage><lpage>2528</lpage><pub-id pub-id-type="doi">10.15252/embj.201696089</pub-id><pub-id pub-id-type="pmid">28673931</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Cheng</surname><given-names>D</given-names></name><name><surname>He</surname><given-names>Z</given-names></name><name><surname>Shi</surname><given-names>X</given-names></name><name><surname>Du</surname><given-names>B</given-names></name><name><surname>Xi</surname><given-names>X</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Guo</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>YAP inhibits autophagy and promotes progression of colorectal cancer via upregulating Bcl-2 expression</article-title><source>Cell Death &amp; Disease</source><volume>12</volume><elocation-id>457</elocation-id><pub-id pub-id-type="doi">10.1038/s41419-021-03722-8</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kapoor</surname><given-names>A</given-names></name><name><surname>Yao</surname><given-names>W</given-names></name><name><surname>Ying</surname><given-names>H</given-names></name><name><surname>Hua</surname><given-names>S</given-names></name><name><surname>Liewen</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Zhong</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>C-J</given-names></name><name><surname>Sadanandam</surname><given-names>A</given-names></name><name><surname>Hu</surname><given-names>B</given-names></name><name><surname>Chang</surname><given-names>Q</given-names></name><name><surname>Chu</surname><given-names>GC</given-names></name><name><surname>Al-Khalil</surname><given-names>R</given-names></name><name><surname>Jiang</surname><given-names>S</given-names></name><name><surname>Xia</surname><given-names>H</given-names></name><name><surname>Fletcher-Sananikone</surname><given-names>E</given-names></name><name><surname>Lim</surname><given-names>C</given-names></name><name><surname>Horwitz</surname><given-names>GI</given-names></name><name><surname>Viale</surname><given-names>A</given-names></name><name><surname>Pettazzoni</surname><given-names>P</given-names></name><name><surname>Sanchez</surname><given-names>N</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Protopopov</surname><given-names>A</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Heffernan</surname><given-names>T</given-names></name><name><surname>Johnson</surname><given-names>RL</given-names></name><name><surname>Chin</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>YA</given-names></name><name><surname>Draetta</surname><given-names>G</given-names></name><name><surname>DePinho</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer</article-title><source>Cell</source><volume>158</volume><fpage>185</fpage><lpage>197</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2014.06.003</pub-id><pub-id pub-id-type="pmid">24954535</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>NG</given-names></name><name><surname>Koh</surname><given-names>E</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Gumbiner</surname><given-names>BM</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>E-cadherin mediates contact inhibition of proliferation through Hippo signaling-pathway components</article-title><source>PNAS</source><volume>108</volume><fpage>11930</fpage><lpage>11935</lpage><pub-id pub-id-type="doi">10.1073/pnas.1103345108</pub-id><pub-id pub-id-type="pmid">21730131</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Jo</surname><given-names>H</given-names></name><name><surname>Hong</surname><given-names>H</given-names></name><name><surname>Kim</surname><given-names>MH</given-names></name><name><surname>Kim</surname><given-names>JM</given-names></name><name><surname>Lee</surname><given-names>JK</given-names></name><name><surname>Heo</surname><given-names>WD</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2015">2015a</year><article-title>Actin remodelling factors control ciliogenesis by regulating YAP/TAZ activity and vesicle trafficking</article-title><source>Nature Communications</source><volume>6</volume><elocation-id>6781</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms7781</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>M</given-names></name><name><surname>Kim</surname><given-names>T</given-names></name><name><surname>Johnson</surname><given-names>RL</given-names></name><name><surname>Lim</surname><given-names>DS</given-names></name></person-group><year iso-8601-date="2015">2015b</year><article-title>Transcriptional co-repressor function of the hippo pathway transducers YAP and TAZ</article-title><source>Cell Reports</source><volume>11</volume><fpage>270</fpage><lpage>282</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2015.03.015</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>W</given-names></name><name><surname>Cho</surname><given-names>YS</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Park</surname><given-names>O</given-names></name><name><surname>Ma</surname><given-names>X</given-names></name><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>Gan</surname><given-names>W</given-names></name><name><surname>Jho</surname><given-names>E</given-names></name><name><surname>Cha</surname><given-names>B</given-names></name><name><surname>Jeung</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Gao</surname><given-names>B</given-names></name><name><surname>Wei</surname><given-names>W</given-names></name><name><surname>Jiang</surname><given-names>J</given-names></name><name><surname>Chung</surname><given-names>K-S</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Hippo signaling is intrinsically regulated during cell cycle progression by APC/C <sup>Cdh1</sup></article-title><source>PNAS</source><volume>116</volume><fpage>9423</fpage><lpage>9432</lpage><pub-id pub-id-type="doi">10.1073/pnas.1821370116</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kulkarni</surname><given-names>A</given-names></name><name><surname>Chang</surname><given-names>MT</given-names></name><name><surname>Vissers</surname><given-names>JHA</given-names></name><name><surname>Dey</surname><given-names>A</given-names></name><name><surname>Harvey</surname><given-names>KF</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The hippo pathway as a driver of select human cancers</article-title><source>Trends in Cancer</source><volume>6</volume><fpage>781</fpage><lpage>796</lpage><pub-id pub-id-type="doi">10.1016/j.trecan.2020.04.004</pub-id><pub-id pub-id-type="pmid">32446746</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lavalée</surname><given-names>M</given-names></name><name><surname>Curdy</surname><given-names>N</given-names></name><name><surname>Laurent</surname><given-names>C</given-names></name><name><surname>Fournié</surname><given-names>J-J</given-names></name><name><surname>Franchini</surname><given-names>D-M</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Cancer cell adaptability: turning ribonucleoprotein granules into targets</article-title><source>Trends in Cancer</source><volume>7</volume><fpage>902</fpage><lpage>915</lpage><pub-id pub-id-type="doi">10.1016/j.trecan.2021.05.006</pub-id><pub-id pub-id-type="pmid">34144941</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>Y</given-names></name><name><surname>Kim</surname><given-names>NH</given-names></name><name><surname>Cho</surname><given-names>ES</given-names></name><name><surname>Yang</surname><given-names>JH</given-names></name><name><surname>Cha</surname><given-names>YH</given-names></name><name><surname>Kang</surname><given-names>HE</given-names></name><name><surname>Yun</surname><given-names>JS</given-names></name><name><surname>Cho</surname><given-names>SB</given-names></name><name><surname>Lee</surname><given-names>SH</given-names></name><name><surname>Paclikova</surname><given-names>P</given-names></name><name><surname>Radaszkiewicz</surname><given-names>TW</given-names></name><name><surname>Bryja</surname><given-names>V</given-names></name><name><surname>Kang</surname><given-names>CG</given-names></name><name><surname>Yuk</surname><given-names>YS</given-names></name><name><surname>Cha</surname><given-names>SY</given-names></name><name><surname>Kim</surname><given-names>SY</given-names></name><name><surname>Kim</surname><given-names>HS</given-names></name><name><surname>Yook</surname><given-names>JI</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Dishevelled has a YAP nuclear export function in a tumor suppressor context-dependent manner</article-title><source>Nature Communications</source><volume>9</volume><elocation-id>2301</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-018-04757-w</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>Y</given-names></name><name><surname>Na</surname><given-names>Z</given-names></name><name><surname>Slavoff</surname><given-names>SA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>P-bodies: composition, properties, and functions</article-title><source>Biochemistry</source><volume>57</volume><fpage>2424</fpage><lpage>2431</lpage><pub-id pub-id-type="doi">10.1021/acs.biochem.7b01162</pub-id><pub-id pub-id-type="pmid">29381060</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>S</given-names></name><name><surname>Meng</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>R</given-names></name><name><surname>Guan</surname><given-names>KL</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The hippo pathway: biology and pathophysiology</article-title><source>Annual Review of Biochemistry</source><volume>88</volume><fpage>577</fpage><lpage>604</lpage><pub-id pub-id-type="doi">10.1146/annurev-biochem-013118-111829</pub-id><pub-id pub-id-type="pmid">30566373</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martínez</surname><given-names>JP</given-names></name><name><surname>Pérez-Vilaró</surname><given-names>G</given-names></name><name><surname>Muthukumar</surname><given-names>Y</given-names></name><name><surname>Scheller</surname><given-names>N</given-names></name><name><surname>Hirsch</surname><given-names>T</given-names></name><name><surname>Diestel</surname><given-names>R</given-names></name><name><surname>Steinmetz</surname><given-names>H</given-names></name><name><surname>Jansen</surname><given-names>R</given-names></name><name><surname>Frank</surname><given-names>R</given-names></name><name><surname>Sasse</surname><given-names>F</given-names></name><name><surname>Meyerhans</surname><given-names>A</given-names></name><name><surname>Díez</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Screening of small molecules affecting mammalian P-body assembly uncovers links with diverse intracellular processes and organelle physiology</article-title><source>RNA Biology</source><volume>10</volume><fpage>1661</fpage><lpage>1669</lpage><pub-id pub-id-type="doi">10.4161/rna.26851</pub-id><pub-id pub-id-type="pmid">24418890</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mason</surname><given-names>DE</given-names></name><name><surname>Collins</surname><given-names>JM</given-names></name><name><surname>Dawahare</surname><given-names>JH</given-names></name><name><surname>Nguyen</surname><given-names>TD</given-names></name><name><surname>Lin</surname><given-names>Y</given-names></name><name><surname>Voytik-Harbin</surname><given-names>SL</given-names></name><name><surname>Zorlutuna</surname><given-names>P</given-names></name><name><surname>Yoder</surname><given-names>MC</given-names></name><name><surname>Boerckel</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>YAP and TAZ limit cytoskeletal and focal adhesion maturation to enable persistent cell motility</article-title><source>The Journal of Cell Biology</source><volume>218</volume><fpage>1369</fpage><lpage>1389</lpage><pub-id pub-id-type="doi">10.1083/jcb.201806065</pub-id><pub-id pub-id-type="pmid">30737263</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mei</surname><given-names>S</given-names></name><name><surname>Qin</surname><given-names>Q</given-names></name><name><surname>Wu</surname><given-names>Q</given-names></name><name><surname>Sun</surname><given-names>H</given-names></name><name><surname>Zheng</surname><given-names>R</given-names></name><name><surname>Zang</surname><given-names>C</given-names></name><name><surname>Zhu</surname><given-names>M</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Shi</surname><given-names>X</given-names></name><name><surname>Taing</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>T</given-names></name><name><surname>Brown</surname><given-names>M</given-names></name><name><surname>Meyer</surname><given-names>CA</given-names></name><name><surname>Liu</surname><given-names>XS</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Cistrome Data Browser: a data portal for ChIP-Seq and chromatin accessibility data in human and mouse</article-title><source>Nucleic Acids Research</source><volume>45</volume><fpage>D658</fpage><lpage>D662</lpage><pub-id pub-id-type="doi">10.1093/nar/gkw983</pub-id><pub-id pub-id-type="pmid">27789702</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Misra</surname><given-names>JR</given-names></name><name><surname>Irvine</surname><given-names>KD</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The hippo signaling network and its biological functions</article-title><source>Annual Review of Genetics</source><volume>52</volume><fpage>65</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1146/annurev-genet-120417-031621</pub-id><pub-id pub-id-type="pmid">30183404</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagaraj</surname><given-names>R</given-names></name><name><surname>Gururaja-Rao</surname><given-names>S</given-names></name><name><surname>Jones</surname><given-names>KT</given-names></name><name><surname>Slattery</surname><given-names>M</given-names></name><name><surname>Negre</surname><given-names>N</given-names></name><name><surname>Braas</surname><given-names>D</given-names></name><name><surname>Christofk</surname><given-names>H</given-names></name><name><surname>White</surname><given-names>KP</given-names></name><name><surname>Mann</surname><given-names>R</given-names></name><name><surname>Banerjee</surname><given-names>U</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Control of mitochondrial structure and function by the Yorkie/YAP oncogenic pathway</article-title><source>Genes &amp; Development</source><volume>26</volume><fpage>2027</fpage><lpage>2037</lpage><pub-id pub-id-type="doi">10.1101/gad.183061.111</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neesse</surname><given-names>A</given-names></name><name><surname>Frese</surname><given-names>KK</given-names></name><name><surname>Bapiro</surname><given-names>TE</given-names></name><name><surname>Nakagawa</surname><given-names>T</given-names></name><name><surname>Sternlicht</surname><given-names>MD</given-names></name><name><surname>Seeley</surname><given-names>TW</given-names></name><name><surname>Pilarsky</surname><given-names>C</given-names></name><name><surname>Jodrell</surname><given-names>DI</given-names></name><name><surname>Spong</surname><given-names>SM</given-names></name><name><surname>Tuveson</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer</article-title><source>PNAS</source><volume>110</volume><fpage>12325</fpage><lpage>12330</lpage><pub-id pub-id-type="doi">10.1073/pnas.1300415110</pub-id><pub-id pub-id-type="pmid">23836645</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>CDK</given-names></name><name><surname>Yi</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>YAP/TAZ signaling and resistance to cancer therapy</article-title><source>Trends in Cancer</source><volume>5</volume><fpage>283</fpage><lpage>296</lpage><pub-id pub-id-type="doi">10.1016/j.trecan.2019.02.010</pub-id><pub-id pub-id-type="pmid">31174841</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pei</surname><given-names>T</given-names></name><name><surname>Luo</surname><given-names>B</given-names></name><name><surname>Huang</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Xiao</surname><given-names>L</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Ouyang</surname><given-names>Y</given-names></name><name><surname>Zhu</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Increased Expression of YAP Inhibited the autophagy level by upregulating mTOR Signal in the Eutopic ESCs of Endometriosis</article-title><source>Frontiers in Endocrinology</source><volume>13</volume><elocation-id>813165</elocation-id><pub-id pub-id-type="doi">10.3389/fendo.2022.813165</pub-id><pub-id pub-id-type="pmid">35173685</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pelletier</surname><given-names>J</given-names></name><name><surname>Thomas</surname><given-names>G</given-names></name><name><surname>Volarević</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Ribosome biogenesis in cancer: new players and therapeutic avenues</article-title><source>Nature Reviews Cancer</source><volume>18</volume><fpage>51</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1038/nrc.2017.104</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piccolo</surname><given-names>S</given-names></name><name><surname>Dupont</surname><given-names>S</given-names></name><name><surname>Cordenonsi</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The biology of YAP/TAZ: hippo signaling and beyond</article-title><source>Physiological Reviews</source><volume>94</volume><fpage>1287</fpage><lpage>1312</lpage><pub-id pub-id-type="doi">10.1152/physrev.00005.2014</pub-id><pub-id pub-id-type="pmid">25287865</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qiao</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Lim</surname><given-names>YB</given-names></name><name><surname>Finch-Edmondson</surname><given-names>ML</given-names></name><name><surname>Seshachalam</surname><given-names>VP</given-names></name><name><surname>Qin</surname><given-names>L</given-names></name><name><surname>Jiang</surname><given-names>T</given-names></name><name><surname>Low</surname><given-names>BC</given-names></name><name><surname>Singh</surname><given-names>H</given-names></name><name><surname>Lim</surname><given-names>CT</given-names></name><name><surname>Sudol</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>YAP regulates actin dynamics through ARHGAP29 and promotes metastasis</article-title><source>Cell Reports</source><volume>19</volume><fpage>1495</fpage><lpage>1502</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2017.04.075</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rausch</surname><given-names>V</given-names></name><name><surname>Bostrom</surname><given-names>JR</given-names></name><name><surname>Park</surname><given-names>J</given-names></name><name><surname>Bravo</surname><given-names>IR</given-names></name><name><surname>Feng</surname><given-names>Y</given-names></name><name><surname>Hay</surname><given-names>DC</given-names></name><name><surname>Link</surname><given-names>BA</given-names></name><name><surname>Hansen</surname><given-names>CG</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The hippo pathway regulates caveolae expression and mediates flow response via caveolae</article-title><source>Current Biology</source><volume>29</volume><fpage>242</fpage><lpage>255</lpage><pub-id pub-id-type="doi">10.1016/j.cub.2018.11.066</pub-id><pub-id pub-id-type="pmid">30595521</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riggs</surname><given-names>CL</given-names></name><name><surname>Kedersha</surname><given-names>N</given-names></name><name><surname>Ivanov</surname><given-names>P</given-names></name><name><surname>Anderson</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Mammalian stress granules and P bodies at a glance</article-title><source>Journal of Cell Science</source><volume>133</volume><elocation-id>science</elocation-id><pub-id pub-id-type="doi">10.1242/jcs.242487</pub-id><pub-id pub-id-type="pmid">32873715</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenbluh</surname><given-names>J</given-names></name><name><surname>Nijhawan</surname><given-names>D</given-names></name><name><surname>Cox</surname><given-names>AG</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Neal</surname><given-names>JT</given-names></name><name><surname>Schafer</surname><given-names>EJ</given-names></name><name><surname>Zack</surname><given-names>TI</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Tsherniak</surname><given-names>A</given-names></name><name><surname>Schinzel</surname><given-names>AC</given-names></name><name><surname>Shao</surname><given-names>DD</given-names></name><name><surname>Schumacher</surname><given-names>SE</given-names></name><name><surname>Weir</surname><given-names>BA</given-names></name><name><surname>Vazquez</surname><given-names>F</given-names></name><name><surname>Cowley</surname><given-names>GS</given-names></name><name><surname>Root</surname><given-names>DE</given-names></name><name><surname>Mesirov</surname><given-names>JP</given-names></name><name><surname>Beroukhim</surname><given-names>R</given-names></name><name><surname>Kuo</surname><given-names>CJ</given-names></name><name><surname>Goessling</surname><given-names>W</given-names></name><name><surname>Hahn</surname><given-names>WC</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>β-Catenin-driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis</article-title><source>Cell</source><volume>151</volume><fpage>1457</fpage><lpage>1473</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2012.11.026</pub-id><pub-id pub-id-type="pmid">23245941</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Russell</surname><given-names>JO</given-names></name><name><surname>Camargo</surname><given-names>FD</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Hippo signalling in the liver: role in development, regeneration and disease</article-title><source>Nature Reviews. Gastroenterology &amp; Hepatology</source><volume>19</volume><fpage>297</fpage><lpage>312</lpage><pub-id pub-id-type="doi">10.1038/s41575-021-00571-w</pub-id><pub-id pub-id-type="pmid">35064256</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shao</surname><given-names>DD</given-names></name><name><surname>Xue</surname><given-names>W</given-names></name><name><surname>Krall</surname><given-names>EB</given-names></name><name><surname>Bhutkar</surname><given-names>A</given-names></name><name><surname>Piccioni</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Schinzel</surname><given-names>AC</given-names></name><name><surname>Sood</surname><given-names>S</given-names></name><name><surname>Rosenbluh</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>JW</given-names></name><name><surname>Zwang</surname><given-names>Y</given-names></name><name><surname>Roberts</surname><given-names>TM</given-names></name><name><surname>Root</surname><given-names>DE</given-names></name><name><surname>Jacks</surname><given-names>T</given-names></name><name><surname>Hahn</surname><given-names>WC</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>KRAS and YAP1 converge to regulate EMT and tumor survival</article-title><source>Cell</source><volume>158</volume><fpage>171</fpage><lpage>184</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2014.06.004</pub-id><pub-id pub-id-type="pmid">24954536</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>Z</given-names></name><name><surname>Stanger</surname><given-names>BZ</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>YAP Regulates S-phase entry in endothelial cells</article-title><source>PLOS ONE</source><volume>10</volume><elocation-id>e0117522</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0117522</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shreberk-Shaked</surname><given-names>M</given-names></name><name><surname>Dassa</surname><given-names>B</given-names></name><name><surname>Sinha</surname><given-names>S</given-names></name><name><surname>Di Agostino</surname><given-names>S</given-names></name><name><surname>Azuri</surname><given-names>I</given-names></name><name><surname>Mukherjee</surname><given-names>S</given-names></name><name><surname>Aylon</surname><given-names>Y</given-names></name><name><surname>Blandino</surname><given-names>G</given-names></name><name><surname>Ruppin</surname><given-names>E</given-names></name><name><surname>Oren</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A Division of Labor between YAP and TAZ in non-small cell lung cancer</article-title><source>Cancer Research</source><volume>80</volume><fpage>4145</fpage><lpage>4157</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-20-0125</pub-id><pub-id pub-id-type="pmid">32816858</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stribinskis</surname><given-names>V</given-names></name><name><surname>Ramos</surname><given-names>KS</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Rpm2p, a protein subunit of mitochondrial RNase P, physically and genetically interacts with cytoplasmic processing bodies</article-title><source>Nucleic Acids Research</source><volume>35</volume><fpage>1301</fpage><lpage>1311</lpage><pub-id pub-id-type="doi">10.1093/nar/gkm023</pub-id><pub-id pub-id-type="pmid">17267405</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>S</given-names></name><name><surname>Irvine</surname><given-names>KD</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Cellular organization and cytoskeletal regulation of the hippo signaling network</article-title><source>Trends in Cell Biology</source><volume>26</volume><fpage>694</fpage><lpage>704</lpage><pub-id pub-id-type="doi">10.1016/j.tcb.2016.05.003</pub-id><pub-id pub-id-type="pmid">27268910</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Totaro</surname><given-names>A</given-names></name><name><surname>Zhuang</surname><given-names>Q</given-names></name><name><surname>Panciera</surname><given-names>T</given-names></name><name><surname>Battilana</surname><given-names>G</given-names></name><name><surname>Azzolin</surname><given-names>L</given-names></name><name><surname>Brumana</surname><given-names>G</given-names></name><name><surname>Gandin</surname><given-names>A</given-names></name><name><surname>Brusatin</surname><given-names>G</given-names></name><name><surname>Cordenonsi</surname><given-names>M</given-names></name><name><surname>Piccolo</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Cell phenotypic plasticity requires autophagic flux driven by YAP/TAZ mechanotransduction</article-title><source>PNAS</source><volume>116</volume><fpage>17848</fpage><lpage>17857</lpage><pub-id pub-id-type="doi">10.1073/pnas.1908228116</pub-id><pub-id pub-id-type="pmid">31416916</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tse</surname><given-names>JR</given-names></name><name><surname>Engler</surname><given-names>AJ</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Preparation of hydrogel substrates with tunable mechanical properties</article-title><source>Current Protocols in Cell Biology</source><volume>47</volume><elocation-id>cb1016s47</elocation-id><pub-id pub-id-type="doi">10.1002/0471143030.cb1016s47</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsherniak</surname><given-names>A</given-names></name><name><surname>Vazquez</surname><given-names>F</given-names></name><name><surname>Montgomery</surname><given-names>PG</given-names></name><name><surname>Weir</surname><given-names>BA</given-names></name><name><surname>Kryukov</surname><given-names>G</given-names></name><name><surname>Cowley</surname><given-names>GS</given-names></name><name><surname>Gill</surname><given-names>S</given-names></name><name><surname>Harrington</surname><given-names>WF</given-names></name><name><surname>Pantel</surname><given-names>S</given-names></name><name><surname>Krill-Burger</surname><given-names>JM</given-names></name><name><surname>Meyers</surname><given-names>RM</given-names></name><name><surname>Ali</surname><given-names>L</given-names></name><name><surname>Goodale</surname><given-names>A</given-names></name><name><surname>Lee</surname><given-names>Y</given-names></name><name><surname>Jiang</surname><given-names>G</given-names></name><name><surname>Hsiao</surname><given-names>J</given-names></name><name><surname>Gerath</surname><given-names>WFJ</given-names></name><name><surname>Howell</surname><given-names>S</given-names></name><name><surname>Merkel</surname><given-names>E</given-names></name><name><surname>Ghandi</surname><given-names>M</given-names></name><name><surname>Garraway</surname><given-names>LA</given-names></name><name><surname>Root</surname><given-names>DE</given-names></name><name><surname>Golub</surname><given-names>TR</given-names></name><name><surname>Boehm</surname><given-names>JS</given-names></name><name><surname>Hahn</surname><given-names>WC</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Defining a cancer dependency map</article-title><source>Cell</source><volume>170</volume><fpage>564</fpage><lpage>576</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.06.010</pub-id><pub-id pub-id-type="pmid">28753430</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Maglic</surname><given-names>D</given-names></name><name><surname>Dill</surname><given-names>MT</given-names></name><name><surname>Mojumdar</surname><given-names>K</given-names></name><name><surname>Ng</surname><given-names>PK-S</given-names></name><name><surname>Jeong</surname><given-names>KJ</given-names></name><name><surname>Tsang</surname><given-names>YH</given-names></name><name><surname>Moreno</surname><given-names>D</given-names></name><name><surname>Bhavana</surname><given-names>VH</given-names></name><name><surname>Peng</surname><given-names>X</given-names></name><name><surname>Ge</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Han</surname><given-names>L</given-names></name><name><surname>Du</surname><given-names>D</given-names></name><name><surname>Creighton</surname><given-names>CJ</given-names></name><name><surname>Mills</surname><given-names>GB</given-names></name><name><surname>Camargo</surname><given-names>F</given-names></name><name><surname>Liang</surname><given-names>H</given-names></name><collab>Cancer Genome Atlas Research Network</collab></person-group><year iso-8601-date="2018">2018</year><article-title>Comprehensive molecular characterization of the hippo signaling pathway in cancer</article-title><source>Cell Reports</source><volume>25</volume><fpage>1304</fpage><lpage>1317</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2018.10.001</pub-id><pub-id pub-id-type="pmid">30380420</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>He</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>B</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Zhu</surname><given-names>H</given-names></name><name><surname>Xu</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Emerging role of the Hippo pathway in autophagy</article-title><source>Cell Death &amp; Disease</source><volume>11</volume><elocation-id>880</elocation-id><pub-id pub-id-type="doi">10.1038/s41419-020-03069-6</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Ruan</surname><given-names>T</given-names></name><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>Tao</surname><given-names>K</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2018">2018a</year><article-title>Overexpression of mRNA-decapping enzyme 1a affects survival rate in colorectal carcinoma</article-title><source>Oncology Letters</source><volume>16</volume><fpage>1095</fpage><lpage>1100</lpage><pub-id pub-id-type="doi">10.3892/ol.2018.8730</pub-id><pub-id pub-id-type="pmid">29963186</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>C</given-names></name><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>Tao</surname><given-names>K</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Ruan</surname><given-names>T</given-names></name><name><surname>Wan</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2018">2018b</year><article-title>MALAT1 promotes the colorectal cancer malignancy by increasing DCP1A expression and miR203 downregulation</article-title><source>Molecular Carcinogenesis</source><volume>57</volume><fpage>1421</fpage><lpage>1431</lpage><pub-id pub-id-type="doi">10.1002/mc.22868</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Minikes</surname><given-names>AM</given-names></name><name><surname>Gao</surname><given-names>M</given-names></name><name><surname>Bian</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Stockwell</surname><given-names>BR</given-names></name><name><surname>Chen</surname><given-names>ZN</given-names></name><name><surname>Jiang</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Intercellular interaction dictates cancer cell ferroptosis via NF2–YAP signalling</article-title><source>Nature</source><volume>572</volume><fpage>402</fpage><lpage>406</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-1426-6</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Jakymiw</surname><given-names>A</given-names></name><name><surname>Wood</surname><given-names>MR</given-names></name><name><surname>Eystathioy</surname><given-names>T</given-names></name><name><surname>Rubin</surname><given-names>RL</given-names></name><name><surname>Fritzler</surname><given-names>MJ</given-names></name><name><surname>Chan</surname><given-names>EKL</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>GW182 is critical for the stability of GW bodies expressed during the cell cycle and cell proliferation</article-title><source>Journal of Cell Science</source><volume>117</volume><fpage>5567</fpage><lpage>5578</lpage><pub-id pub-id-type="doi">10.1242/jcs.01477</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Chong</surname><given-names>R</given-names></name><name><surname>Ding</surname><given-names>SJ</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Dong</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>CDK1 Phosphorylation of YAP promotes mitotic defects and cell motility and is essential for neoplastic transformation</article-title><source>Cancer Research</source><volume>73</volume><fpage>6722</fpage><lpage>6733</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-13-2049</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoon</surname><given-names>JH</given-names></name><name><surname>Choi</surname><given-names>EJ</given-names></name><name><surname>Parker</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Dcp2 phosphorylation by Ste20 modulates stress granule assembly and mRNA decay in <italic>Saccharomyces cerevisiae</italic></article-title><source>The Journal of Cell Biology</source><volume>189</volume><fpage>813</fpage><lpage>827</lpage><pub-id pub-id-type="doi">10.1083/jcb.200912019</pub-id><pub-id pub-id-type="pmid">20513766</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>FX</given-names></name><name><surname>Zhao</surname><given-names>B</given-names></name><name><surname>Panupinthu</surname><given-names>N</given-names></name><name><surname>Jewell</surname><given-names>JL</given-names></name><name><surname>Lian</surname><given-names>I</given-names></name><name><surname>Wang</surname><given-names>LH</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Yuan</surname><given-names>H</given-names></name><name><surname>Tumaneng</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Fu</surname><given-names>XD</given-names></name><name><surname>Mills</surname><given-names>GB</given-names></name><name><surname>Guan</surname><given-names>KL</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling</article-title><source>Cell</source><volume>150</volume><fpage>780</fpage><lpage>791</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2012.06.037</pub-id><pub-id pub-id-type="pmid">22863277</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zanconato</surname><given-names>F</given-names></name><name><surname>Forcato</surname><given-names>M</given-names></name><name><surname>Battilana</surname><given-names>G</given-names></name><name><surname>Azzolin</surname><given-names>L</given-names></name><name><surname>Quaranta</surname><given-names>E</given-names></name><name><surname>Bodega</surname><given-names>B</given-names></name><name><surname>Rosato</surname><given-names>A</given-names></name><name><surname>Bicciato</surname><given-names>S</given-names></name><name><surname>Cordenonsi</surname><given-names>M</given-names></name><name><surname>Piccolo</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Genome-wide association between YAP/TAZ/TEAD and AP-1 at enhancers drives oncogenic growth</article-title><source>Nature Cell Biology</source><volume>17</volume><fpage>1218</fpage><lpage>1227</lpage><pub-id pub-id-type="doi">10.1038/ncb3216</pub-id><pub-id pub-id-type="pmid">26258633</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zanconato</surname><given-names>F</given-names></name><name><surname>Cordenonsi</surname><given-names>M</given-names></name><name><surname>Piccolo</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>YAP/TAZ at the roots of cancer</article-title><source>Cancer Cell</source><volume>29</volume><fpage>783</fpage><lpage>803</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2016.05.005</pub-id><pub-id pub-id-type="pmid">27300434</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Nandakumar</surname><given-names>N</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Manzano</surname><given-names>M</given-names></name><name><surname>Smith</surname><given-names>A</given-names></name><name><surname>Graham</surname><given-names>G</given-names></name><name><surname>Gupta</surname><given-names>S</given-names></name><name><surname>Vietsch</surname><given-names>EE</given-names></name><name><surname>Laughlin</surname><given-names>SZ</given-names></name><name><surname>Wadhwa</surname><given-names>M</given-names></name><name><surname>Chetram</surname><given-names>M</given-names></name><name><surname>Joshi</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Kallakury</surname><given-names>B</given-names></name><name><surname>Toretsky</surname><given-names>J</given-names></name><name><surname>Wellstein</surname><given-names>A</given-names></name><name><surname>Yi</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Downstream of Mutant KRAS, the transcription regulator YAP Is essential for neoplastic progression to pancreatic ductal adenocarcinoma</article-title><source>Science Signaling</source><volume>7</volume><elocation-id>ra42</elocation-id><pub-id pub-id-type="doi">10.1126/scisignal.2005049</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>B</given-names></name><name><surname>Wei</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Udan</surname><given-names>RS</given-names></name><name><surname>Yang</surname><given-names>Q</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Xie</surname><given-names>J</given-names></name><name><surname>Ikenoue</surname><given-names>T</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Zheng</surname><given-names>P</given-names></name><name><surname>Ye</surname><given-names>K</given-names></name><name><surname>Chinnaiyan</surname><given-names>A</given-names></name><name><surname>Halder</surname><given-names>G</given-names></name><name><surname>Lai</surname><given-names>ZC</given-names></name><name><surname>Guan</surname><given-names>KL</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control</article-title><source>Genes &amp; Development</source><volume>21</volume><fpage>2747</fpage><lpage>2761</lpage><pub-id pub-id-type="doi">10.1101/gad.1602907</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Bi</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Su</surname><given-names>W</given-names></name><name><surname>Hernandez</surname><given-names>K</given-names></name><name><surname>Liu</surname><given-names>P</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Huang</surname><given-names>TH-M</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>A Non-canonical Role of YAP/TEAD Is required for activation of estrogen-regulated enhancers in breast cancer</article-title><source>Molecular Cell</source><volume>75</volume><fpage>791</fpage><lpage>806</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2019.06.010</pub-id><pub-id pub-id-type="pmid">31303470</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>Z</given-names></name><name><surname>Song</surname><given-names>J</given-names></name><name><surname>Guo</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Dang</surname><given-names>X</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Ou</surname><given-names>W</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Yu</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>CY</given-names></name><name><surname>Cui</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>LAMB3 promotes tumour progression through the AKT–FOXO3/4 axis and is transcriptionally regulated by the BRD2/acetylated ELK4 complex in colorectal cancer</article-title><source>Oncogene</source><volume>39</volume><fpage>4666</fpage><lpage>4680</lpage><pub-id pub-id-type="doi">10.1038/s41388-020-1321-5</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.88573.3.sa0</article-id><title-group><article-title>eLife assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Yongliang</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>Dalian University of Technology</institution><country>China</country></aff></contrib></contrib-group><kwd-group kwd-group-type="evidence-strength"><kwd>Convincing</kwd></kwd-group><kwd-group kwd-group-type="claim-importance"><kwd>Valuable</kwd></kwd-group></front-stub><body><p>This <bold>valuable</bold> study advances our understanding that YAP/TAZ, as well as their target genes, plays a prominent role in the formation of processing bodies (P-bodies). The evidence supporting the conclusions is <bold>convincing</bold>. The article could be improved through further analysis to elucidate the mechanistic link between P-body formation and oncogenesis. The work will be of broad interest to scientists working in the field of Hippo signaling and cancer biology.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.88573.3.sa1</article-id><title-group><article-title>Reviewer #2 (Public Review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>In a study by Shen et al.. al., the authors investigated YAP/TAZ target genes that play a role in the formation of processing bodies (P-bodies). P-bodies are membraneless cytoplasmic granules that contain translationally repressed mRNAs and components of mRNA turnover. GO enrichment analysis of the RNA-Seq data of colorectal cancer cells (HCT116) after YAP/TAZ knockdown showed that the downregulated genes were enriched in P-body resident proteins. Overexpression, knockdown, and ChIP-qPCR analyses showed that SAMD4A, PNRC1, AJUBA, and WTIP are YAP-TEAD target genes that also play a role in P-body biogenesis. Using P-body markers such as DDX6 and DCP1A, the authors showed that knockdown of YAP in the HCT116 cell line causes a reduction in the number of P-bodies. Similarly, overexpression of constitutively active YAP (YAP 5SA) increased the P-body number. The YAP-TEAD target genes SAMD4A and AJUBA positively regulate P-body formation, because lowering their expression levels using siRNA reduces the number of P-bodies. The other YAP target gene, PNRC1, is a negative regulator of P-body biogenesis and consistently YAP suppresses its expression through the recruitment of the NuRD complex. YAP target genes that modulate P-body formation play prominent roles in oncogenesis. PNRC1 suppression is key to YAP-mediated proliferation, colony formation, and tumorigenesis in HCT116 xenografts. Similarly, SAMD4 and AJUBA knockdown abrogated cell viability. In summary, this study demonstrated that SAMD4, AJUBA, WTIP, and PNRC1 are bona fide YAP-TEAD target genes that play a role in P-body formation, which is also linked to the oncogenesis of colon cancer cells.</p><p>Major Strengths:</p><p>The majority of the experiments were appropriately planned so that the generated data could support the conclusions drawn by the authors. The phenotype observed with YAP/TAZ knockdown correlated inversely with YAP5SA overexpression, which is complementary. Where possible, the authors also used point mutations that selectively disrupt protein-protein interactions, such as YAP S94A and PNRC1 W300A. The CRC cell line HCT116 was used throughout the study; additionally, data from other cancer cell lines were used to support the generality of the findings.</p><p>Weaknesses:</p><p>The authors did not elucidate the mechanistic link between P-body formation and oncogenesis; therefore, it is unclear why an increase in the number of P-bodies is pro-tumorigenic. The authors extrapolated and suggested that PNRC1 expression could be exploited therapeutically, without providing much detail. How do they plan to stimulate the expression of PNRC1? It is not necessary for every scientific finding to lead to a therapeutic benefit; therefore, they can tone down such statements if therapeutic exploitation is not realistic. The authors elucidated a mechanism for PNRC1 repression and one wonders why no attempts were made to understand the mechanism of activation of SAMD4, AJUBA, and WTIP expression.</p></body></sub-article><sub-article article-type="author-comment" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.88573.3.sa2</article-id><title-group><article-title>Author response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Shen</surname><given-names>Xia</given-names></name><role specific-use="author">Author</role><aff><institution>Department of Colorectal and Anal Surgery, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</institution><addr-line><named-content content-type="city">shanghai</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Peng</surname><given-names>Xiang</given-names></name><role specific-use="author">Author</role><aff><institution>Department of Colorectal and Anal Surgery, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</institution><addr-line><named-content content-type="city">shanghai</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Guo</surname><given-names>YueGui</given-names></name><role specific-use="author">Author</role><aff><institution>Department of Colorectal and Anal Surgery, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</institution><addr-line><named-content content-type="city">shanghai</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Dai</surname><given-names>Zhujiang</given-names></name><role specific-use="author">Author</role><aff><institution>Department of Colorectal and Anal Surgery, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</institution><addr-line><named-content content-type="city">shanghai</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Cui</surname><given-names>Long</given-names></name><role specific-use="author">Author</role><aff><institution>Department of Colorectal and Anal Surgery, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</institution><addr-line><named-content content-type="city">shanghai</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Yu</surname><given-names>Wei</given-names></name><role specific-use="author">Author</role><aff><institution>Fudan University</institution><addr-line><named-content content-type="city">Shanghai</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Yun</given-names></name><role specific-use="author">Author</role><aff><institution>Department of Colorectal and Anal Surgery, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</institution><addr-line><named-content content-type="city">shanghai</named-content></addr-line><country>China</country></aff></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Chen-Ying</given-names></name><role specific-use="author">Author</role><aff><institution>Department of Colorectal and Anal Surgery, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</institution><addr-line><named-content content-type="city">shanghai</named-content></addr-line><country>China</country></aff></contrib></contrib-group></front-stub><body><p>The following is the authors’ response to the original reviews.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #1 (Public Review):</bold></p><p>In this manuscript, the authors demonstrated that YAP/TAZ promotes P-body formation in a series of cancer cell lines. YAP/TAZ modulates the transcription of multiple P-body-related genes, especially repressing the transcription of the tumor suppressor proline-rich nuclear receptor coactivator 1 (PNRC1) through cooperation with the NuRD complex. PNRC1 functions as a critical repressor in YAP-induced biogenesis of P-bodies and tumorigenesis in colorectal cancer (CRC). Reexpression of PNRC1 or disruption of P-bodies attenuated the protumorigenic effects of YAP. Overall, these findings are interesting and the study was well conducted.</p></disp-quote><p>We thank the reviewer for the positive comments for our work.</p><disp-quote content-type="editor-comment"><p>Major concerns:</p><p>(1) RNAseq data indicated that Yap has the capacity to suppress the expression of numerous genes. In addition to PNRC1, could there be additional Yap targeting factors involved in Yap-mediated the formation of P-bodies?</p></disp-quote><p>Yes, indeed. Additional YAP target genes, such as AJUBA, SAMD4A, are also involved in YAP-mediated the formation of P-bodies (Fig. 1B-D). Knockdown of either SMAD4A or AJUBA attenuated the P-body formation induced by overexpression of YAP5SA (Fig. 3A).</p><disp-quote content-type="editor-comment"><p>(2) It is still not clear how PNRC1 regulates P-bodies. Knockdown of PNRC1 prevented the reduction of P-bodies caused by Yap knockdown. How do the genes related to P-bodies that are positively regulated by Yap, such as SAMD4A, AJUBA, and WTIP, change in this scenario? Given that the expression of Yap can differ considerably among various cell types, is it possible for P-bodies to be present in tumor cells lacking Yap expression?</p></disp-quote><p>The detail mechanism of PNRC1’s suppressive effect on P-body formation was well explored in Gaviraghi et al.’s paper, in which PNRC1 was first identified as a tumor suppressor gene (EMBO, 2018, PMID: 30373810). Gaviraghi et al. revealed that overexpression of PNRC1 leads to translocation of cytoplasmic DCP1A/DCP2 into the nucleolus, which subsequently attenuates rRNA transcription and ribosome biogenesis. Since DCP1A and DCP2 are essential for formation of P-bodies, loss of cytoplasmic DCP1A/DCP2 also disrupts P-body formation. This background information has been included in the Results and Discussion sections in the manuscript:</p><p>Previously, we have performed the RNA-seq analysis of HCT116 cells with overexpression of PNRC1. Compared with YAP5SA overexpression (520 differentially expressed genes), overexpression of PNRC1 showed less effect on the gene expression profile (147 differentially expressed genes) and expression of SAMD4A, AJUBA and WTIP were not affected by PNRC1 overexpression.</p><p>In this study, we found that YAP could promote P-body formation in a series of cancer cell lines. During the exploration, we observed that P-bodies hardly existed in the RKO colorectal cancer cell line (Figure 1 for the reviewer). However, the regulatory effect of YAP/TAZ on SAMD4A, AJUBA, and WTIP was still observed (Figure 2 for the reviewer). These data suggest that YAP’s activity could be sufficient but not required for the P-body formation. So, we agree that P-bodies could be present in tumor cells lacking Yap expression.</p><fig id="sa2fig1" position="float"><label>Author response image 1.</label><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-88573-sa2-fig1-v1.tif"/></fig><fig id="sa2fig2" position="float"><label>Author response image 2.</label><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-88573-sa2-fig2-v1.tif"/></fig><disp-quote content-type="editor-comment"><p>(3) The authors demonstrated that CHD4 can bind to Yap target genes, such as CTGF, AJUBA, SAMD4A (Figure 4 - Figure Supplement 1D). Does the NuRD complex repress the expression of these genes? the NuRD complex could prevent the formation of P-bodies?</p></disp-quote><p>Good point! Following the reviewer’s suggestions, we detected the mRNA levels of AJUBA, WTIP and SAMD4A, and the P-body formation the CHD4 knockdown cells. Interestingly, knockdown of CHD4 induced mild downregulation of AJUBA, WTIP and SAMD4A in HCT116 cells (Figure 3 for the reviewer). Of note, NuRD complex is involved in both transcriptional repression and activation (PNAS 2011, PMID: 21490301; Stem Cell Reports. 2021, PMID: 33961790). As expected, knockdown CHD4 induced decreased number of P-bodies in HCT116 cell (new Figure 4-Supplement 1E), which is consistent to the enhanced expression of PNRC1 (Figure 4F).</p><fig id="sa2fig3" position="float"><label>Author response image 3.</label><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-88573-sa2-fig3-v1.tif"/></fig><fig id="sa2fig4" position="float"><label>Author response image 4.</label><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-88573-sa2-fig4-v1.tif"/></fig><disp-quote content-type="editor-comment"><p>(4) YAP/TAZ promotes the formation of P-bodies which contradicts the previous study's conclusion (PMID: 34516278). Please address these inconsistent findings.</p></disp-quote><p>The contradictory observations between our and the previous studies could be due to the different cell lines (HUVEC vs cancer cell lines) and different stimuli (KHSV infection vs normal culture condition or serum stimulation, cell density and stiffness). Actually, we have discussed the contradictory observation in the previous study in the Discussion section as followed:</p><p>“In contrast, a recent study, which provided the first link between YAP and P-bodies, implicated YAP as a negative regulator of P-bodies in KHSV-infected HUVECs (Castle et al, 2021). Elizabeth L. Castle et al. reported that virus-encoded Kaposin B (KapB) induces actin stress fiber formation and disassembly of P-bodies, which requires RhoA activity and the YAP transcriptional program (Castle et al, 2021). YAP-enhanced autophagic flux was proposed to participate in KapB-induced P-body disassembly, consistent with the concept that stress granules and P-bodies are cleared by autophagy (Buchan et al, 2013; Castle et al, 2021). However, an increasing number of studies have reported the contradictory role of YAP in autophagy regulation, which suggests that YAP-mediated autophagy regulation is cell type- and context-dependent (Jin et al, 2021; Pei et al, 2022; Totaro et al, 2019; Wang et al, 2020). Furthermore, though YAP is required for the cell proliferation in HUVEC, transformed cell lines often display elevated baseline YAP/TAZ activity compared to normal cells and possess many alterations in growth signaling pathways including autophagy signaling (Nguyen &amp; Yi, 2019; Shen &amp; Stanger, 2015; Zanconato et al, 2016). Thus, the contradictory observations regarding the role of YAP in modulating P-body formation between Elizabeth L. Castle et al.’s study and our study could be due to the different cell contexts and different cell conditions (baseline vs. KHSV infection).”</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Public Review):</bold></p><p>In a study by Shen et al., the authors investigated YAP/TAZ target genes that play a role in the formation of processing bodies (P-bodies). P-bodies are membraneless cytoplasmic granules that contain translationally repressed mRNAs and components of mRNA turnover. GO enrichment analysis of the RNA-Seq data of colorectal cancer cells (HCT116) after YAP/TAZ knockdown showed that the downregulated genes were enriched in P-body resident proteins. Overexpression, knockdown, and ChIP-qPCR analyses showed that SAMD4A, PNRC1, AJUBA, and WTIP are YAP-TEAD target genes that also play a role in P-body biogenesis. Using P-body markers such as DDX6 and DCP1A, the authors showed that the knockdown of YAP in the HCT116 cell line causes a reduction in the number of P-bodies. Similarly, overexpression of constitutively active YAP (YAP 5SA) increased the P-body number. The YAP-TEAD target genes SAMD4A and AJUBA positively regulate P-body formation, because lowering their expression levels using siRNA reduces the number of P-bodies. The other YAP target gene, PNRC1, is a negative regulator of P-body biogenesis and consistently YAP suppresses its expression through the recruitment of the NuRD complex. YAP target genes that modulate P-body formation play prominent roles in oncogenesis. PNRC1 suppression is key to YAP-mediated proliferation, colony formation, and tumorigenesis in HCT116 xenografts. Similarly, SAMD4 and AJUBA knockdown abrogated cell viability. In summary, this study demonstrated that SAMD4, AJUBA, WTIP, and PNRC1 are bona fide YAP-TEAD target genes that play a role in P-body formation, which is also linked to the oncogenesis of colon cancer cells.</p></disp-quote><p>We thank the reviewer for the positive comments for our work.</p><disp-quote content-type="editor-comment"><p>Major Strengths:</p><p>The majority of the experiments were appropriately planned so that the generated data could support the conclusions drawn by the authors. The phenotype observed with YAP/TAZ knockdown correlated inversely with YAP5SA overexpression, which is complementary. Where possible, the authors also used point mutations that selectively disrupt protein-protein interactions, such as YAP S94A and PNRC1 W300A. The CRC cell line HCT116 was used throughout the study; additionally, data from other cancer cell lines were used to support the generality of the findings.</p></disp-quote><p>We thank the reviewer for the positive comments regarding the strength and significance of our work.</p><disp-quote content-type="editor-comment"><p>Weaknesses:</p><p>The authors did not elucidate the mechanistic link between P-body formation and oncogenesis; therefore, it is unclear why an increase in the number of P-bodies is pro-tumorigenic. AJUBA and SAMD4 may have housekeeping functions and reduce the proliferation of YAP-independent cell lines. Figure 6 - Figure Supplement 4 shows a reduction in cell viability and migration in control HCT116 cell lines upon AJUBA/SAMD4 knockdown. Therefore, it is unclear whether their tumor suppressive role is YAP-dependent. The authors extrapolated and suggested that their findings could be exploited therapeutically, without providing much detail. How do they plan to stimulate the expression of PNRC1? It is not necessary for every scientific finding to lead to a therapeutic benefit; therefore, they can tone down such statements if therapeutic exploitation is not realistic. The authors elucidated a mechanism for PNRC1 repression and one wonders why no attempts were made to understand the mechanism of activation of SAMD4, AJUBA, and WTIP expression.</p></disp-quote><p>We thank the reviewer for pointing out these issues to further improve the quality of our study. As mentioned in the Abstract section, the role of P-bodies in tumorigenesis and tumor progression is not well studied. In this study, we revealed that disruption of P-body formation by knockdown of essential P-body-related genes attenuates YAP-driven oncogenic function in CRC, which provides evidence implicating the pro-tumorigenic role of P-bodies. We agree with the reviewer that the mechanism of P-body formation promoting tumorigenesis is an important scientific question warranting exploration and plan to investigate this fancy question in next study.</p><p>AJUBA has been known to act as a signal transducer in oncogenesis and promote CRC cell survival (Pharmacol Res. 2020, PMID: 31740385; Oncogene. 2017, PMID: 27893714). Furthermore, as the reviewer suggested, we found that knockdown of both AJUBA and SAMD4A suppressed the cell proliferation in the YAP-deficient cell line, SHP-77, which further implicates the oncogenic role of AJUBA and SAMD4A (Figure 4 for the reviewer). Numerous studies have shown that YAP/TAZ knockdown suppressed the cell proliferation of HCT116 cells. Thus, not surprisingly, knockdown of AJUBA and SAMD4A also repressed the cell proliferation of the “parental” control HCT116 cells. Since the molecular mechanistic studies identified the AJUBA and SAMD4A were bona fide YAP-TEAD target genes, the co-dependencies of YAP and AJUBA/SAMD4A in the HCT116 cells imply that the pro-tumorigenic function of YAP could be dependent on activation of AJUBA/SAMD4A, in some extent (due to the large amount of YAP target genes).</p><fig id="sa2fig5" position="float"><label>Author response image 5.</label><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-88573-sa2-fig5-v1.tif"/></fig><p>Tumor suppressor genes are frequently epigenetically silenced in cancer cells, so is PNRC1. In our preliminary study, we found that the DNA methyltransferase inhibitor 5-Azacytidine dramatically increased the mRNA level of PNRC1 in HCT116 cells (Figure 5 for the reviewer), which suggests that PNRC1 is epigenetically suppressed by DNA methylation in CRC cells and could be re-activated or re-expressed by DNA methyltransferase inhibitor for the cancer treatment.</p><fig id="sa2fig6" position="float"><label>Author response image 6.</label><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-88573-sa2-fig6-v1.tif"/></fig><p>YAP/TAZ are well-known as transcriptional co-activators and the mechanism of transcriptional activation of target genes has been well-studied (Cell Stress. 2021, PMID: 34782888). However, years later, the function of YAP/TAZ as the transcriptional co-repressors was brought to the forefront. Both NuRD and Polycomb repressive complex 2 (PRC2) are involved in the transcriptional repressor function of YAP (Cell Rep. 2015, PMID: 25843714; Cancer Res. 2020, PMID: 32409309). Thus, we focused on exploring mechanism for PNRC1 repression in this study, but not the mechanism of activation of SAMD4A, AJUBA, and WTIP expression.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Recommendations For The Authors):</bold></p><p>Suggested experiments: The suggested experiments were aimed at minimizing the weaknesses of the manuscript. The roles of AJUBA and SAMD4 can be elucidated in a YAP-independent cell line. After knockdown of AJUBA or SAMD4 in a YAP-independent cell line, the effects on proliferation and migration should be determined.</p></disp-quote><p>Following the reviewer’s suggestions, we explored the role of AJUBA and SAMD4A in the YAP-independent cell line, SHP-77 (Cancer Cell. 2021, PMID: 34270926). Unfortunately, SHP-77 cells are suspension cells mixed with some loosely adherent cells, and we found that SHP-77 cells are not available for cell migration assay. By CCK8 assay, we found that knockdown of both AJUBA and SAMD4A suppressed the cell proliferation in SHP-77 cells, which further implicates the oncogenic role of AJUBA and SAMD4A.</p><fig id="sa2fig7" position="float"><label>Author response image 7.</label><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-88573-sa2-fig7-v1.tif"/></fig><disp-quote content-type="editor-comment"><p>Experiments directed at elucidating whether the mRNAs of tumor suppressor genes undergo sequestration and decay in P-bodies that ultimately promote tumorigenesis will provide a mechanistic link between P-body formation and tumorigenesis. The enrichment of P-bodies through biochemical methods has been employed in other studies. RNA-seq after P-body enrichment may provide opportunities to unravel the link between P-body formation and tumorigenesis.</p></disp-quote><p>We thank the reviewer for the constructive suggestions to further improve the significance of our study. We do have plans to purify the P-bodies to further elucidate underlying mechanisms of pro-tumorigenic role of P-bodies tumor cells. However, we are newcomers in the P-body field and encountered a lot of issues to establish the biochemical assays of P-bodies. Hopefully, we can solve these technical issues soon and present our new data in the next paper.</p></body></sub-article></article>